WO2015138600A2 - Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies - Google Patents
Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies Download PDFInfo
- Publication number
- WO2015138600A2 WO2015138600A2 PCT/US2015/019954 US2015019954W WO2015138600A2 WO 2015138600 A2 WO2015138600 A2 WO 2015138600A2 US 2015019954 W US2015019954 W US 2015019954W WO 2015138600 A2 WO2015138600 A2 WO 2015138600A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- seq
- amino acid
- antibodies
- set forth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Definitions
- Turnover of cells begins with the induction of an apoptotic program or other cellular changes that mark them for removal, and the subsequent recognition of markers by phagocytes, including macrophages, dendritic cells, and the like. This process requires a specific and selective removal of unwanted cells. Unlike healthy cells, the unwanted/aged/dying cells display markers or ligands called "eat-me” signals, i.e. "altered self", which can in turn be recognized by receptors on the phagocytes.
- Healthy cells may display "don't eat-me” signals that actively inhibit phagocytosis; these signals are either downregulated in the dying cells, are present in an altered conformation or they are superseded by the upregulation of "eat-me” or pro-phagocytic signals.
- the cell surface protein CD47 on healthy cells and its engagement of a phagocyte receptor, SIRPa constitutes a key "don't eat-me” signal that can turn off engulfment mediated by multiple modalities, including apoptotic cell clearance and FcR mediated phagocytosis. Blocking the CD47 mediated engagement of SIRPa on a phagocyte can cause removal of live cells bearing "eat me” signals.
- CD47 is a broadly expressed transmembrane glycoprotein with a single Ig-like domain and five membrane spanning regions, which functions as a cellular ligand for SIRPa with binding mediated through the NH2-terminal V-like domain of SIRPa.
- SIRPa is expressed primarily on myeloid cells, including macrophages, granulocytes, myeloid dendritic cells (DCs), mast cells, and their precursors, including hematopoietic stem cells.
- Structural determinants on SIRPa that mediate CD47 binding are discussed by Lee et al. (2007) J. Immunol. 179:7741 - 7750; Hatherley et al. (2007) J. B.C.
- PCD programmed cell death
- phagocytic cell removal are common ways that an organism responds in order to remove damaged, precancerous, or infected cells.
- Cells that survive this host response e.g., cancerous cells, chronically infected cells, etc.
- CD47 the "don't eat me" signal, is constitutively upregulated on a wide variety of diseased cells, cancer cells, and infected cells, allowing these cells to evade phagocytosis.
- Anti-CD47 agents that block the interaction between CD47 on one cell (e.g., a cancer cell, an infected cell, etc.) and SIRPa on another cell
- anti-CD47 agents can be used to treat and/or protect against a wide variety of conditions/disorders.
- anti-CD47 and anti- SIRPa blocking antibodies significantly increase phagocytosis of cancer cells in vitro and in vivo. They have been shown to be effective at treating mice engrafted with a wide range of human cancers, from leukemias to solid tumors.
- an initial high dose of an anti-CD47 agent can cause a dose-dependent loss of red blood cells (RBCs) in mice and non-human primate (NHP) models by binding to CD47 on the surface of the RBCs.
- RBCs red blood cells
- NHS non-human primate
- the severity of this anemia can preclude the use of higher doses that are required to achieve sustained serum concentrations associated with therapeutic efficacy.
- the present disclosure provides anti-SI RPa antibodies that block the interaction of CD47 on one cell (e.g., a cancer cell, an infected cell, etc.) with SIRPa on another cell (e.g., a phagocytic cell), and facilitate the phagocytosis of the CD47-expressing cell.
- a cell e.g., a cancer cell, an infected cell, etc.
- SIRPa e.g., a phagocytic cell
- antibodies that are bispecific for SIRPa and a second antigen e.g., a tumor antigen.
- These bi- specific macrophage enhancing (BiME) antibodies exhibit enhanced properties.
- compositions and methods are provided relating to anti-SI RPa antibodies.
- the antibodies of the disclosure bind to human SIRPa and can block the interaction of CD47 expressed on a target cell of interest with SIRPa expressed on a phagocytic cell.
- the subject antibodies find use in various therapeutic methods.
- an anti-SIRPa antibody of the invention can bind SIRPa, but does not stimulate SIRPa signaling in the cell expressing the SI RPa.
- Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the subject anti- SI RPa antibodies; and cell lines that produce these anti-SIRPa antibodies. Also provided are amino acid sequences of exemplary antibodies.
- Antibodies of interest include the provided anti- SIRPa antibodies, and variants thereof.
- the anti-SIRPa antibodies of the disclosure find particular utility as reagents for the treatment of diseases associated with CD47 in humans (e.g., cancer, chronic infection, etc.)
- an anti-SIRPa antibody may be a full length chimeric or humanized antibody, e.g. having a human immunoglobulin constant region of any isotype or modification, e.g. lgG1 , lgG2, lgG3, lgG4, IgA, eic; or an antibody fragment, e.g. a F(ab') 2 fragment, and F(ab) fragment, etc. Fragments comprising CDR regions are also of interest.
- Exemplary forms also include single-chain Fv species (scFv) having one heavy- and one light-chain variable domain that are covalently linked by a flexible peptide linker.
- the antibody may be labeled with a detectable label, immobilized on a solid phase and/or conjugated with a heterologous compound.
- the antibody may also be provided as a bispecific or multispecific antibody reactive with a second antigen, particularly including cancer antigens and/or antigens of chronic infection.
- compositions that include a subject anti-SIRPa antibody and an antibody that binds to a second antigen (e.g., a cancer cell marker, a marker of chronic infection, and the like).
- kits comprising the antibody and instructions for using the antibody.
- the antibodies of the disclosure are efficacious in the treatment of disease.
- method of treatment comprising contacting an individual with an effective dose of an antibody of the invention, wherein the effective dose provides for binding the antibody of the invention to a phagocytic cell thereby increasing phagocytosis of target cells expressing CD47.
- Treatment may be systemic or localized, e.g. delivery by intratumoral injection, etc.
- Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof that comprise at least one, usually at least 3 CDR sequences from a set, as provided herein, usually in combination with framework sequences from a human variable region.
- an antibody or derivative or fragment thereof comprises at least one light chain comprising a set of 3 light chain CDR sequences provided herein, situated in a variable region framework, which may be, without limitation, a human, canine, mouse, etc. variable region framework; and at least one heavy chain comprising the set of 3 heavy chain CDR sequence provided herein, situated in a variable region framework, which may be, without limitation, a human, canine, mouse, etc. variable region framework or other appropriate protein scaffold.
- the antibody comprises an amino acid sequence variant of one or more of the CDRs of the provided antibodies, which variant comprises one or more amino acid insertion(s) within or adjacent to a CDR residue and/or deletion(s) within or adjacent to a CDR residue and/or substitution(s) of CDR residue(s) (with substitution(s) being the preferred type of amino acid alteration for generating such variants).
- Such variants will normally having a binding affinity for human SIRPa of 10 "5 M or better (e.g., 10 "6 M or better, 10 "8 M or better, etc.) and will bind to the same epitope as an antibody having the amino acid sequence of those set forth herein.
- the disclosure further provides: isolated nucleic acids encoding the antibodies and variants thereof; a vector comprising that nucleic acid, optionally operably linked to control sequences recognized by a host cell transformed with the vector; a host cell comprising that vector; a process for producing the antibody comprising culturing the host cell so that the nucleic acid is expressed and, optionally, recovering the antibody from the host cell culture (e.g. from the host cell culture medium).
- the disclosure also provides a composition comprising one or more of the anti-SIRPa antibodies and a pharmaceutically acceptable carrier or diluent. This composition for therapeutic use is sterile and may be lyophilized, e.g. being provided as a prepack in a unit dose with diluent and delivery device, e.g. inhaler, syringe, etc.
- FIGS 1A-C Figures 1A-C.
- KWAR23 a monoclonal CD47-blocking anti-human SIRPa antibody.
- A- B Assays of KWAR23 binding to SIRPa by blocking CD47 binding to THP-1 cells (a SIRPa expressing cell line used to investigate the function and regulation of monocytes and macrophages).
- LH and HL monomers are engineered KWAR23 scFv monomers having a light chain with KWAR23 CDRs linked via linker to a heavy chain with KWAR23 CDRs (HL, N- terminal heavy-chain; LH, N-terminal light-chain).
- "Geo. MFI" is geometric mean fluorescence intensity.
- C KWAR23 scFv blocks CD47 binding, as assayed by measuring CD47 binding to SI RPa-displaying yeast.
- Figure 2A-C depicts phagocytosis of cancer cells by human macrophages in the presence of the indicated antibody (cetuximab, trastuzumab, or rituximab) plus or minus the KWAR23 antibody.
- cetuximab anti-EGFR, DLD-1 cells
- Trastuzumab anti-HER2, SKBR3 cells
- Rituximab anti-CD20, Raji cells
- Figure 3 KWAR 23 enhances the efficacy of all human IgG isotypes.
- A KWAR23 enhanced the efficacy of anti-CD20 for all tested IgG isotypes.
- B KWAR23 enhanced the efficacy of both tested isotypes of anti-EGFR (epidermal growth factor receptor). Although they both target EGFR, panitumumab (lgG2) and cetuximab (lgG1 ) differ in their isotype.
- EGFR epidermal growth factor receptor
- FIGS 4A-C Bispecific Macrophage Enhacing (BiME) antibodies.
- A Schematic of activity of exemplary subject bispecific antibodies, which activities include engaging Fc receptors on macrophages, activating ITAMs; blocking CD47-SIRP interaction, removing ITIM inhibition; and physically cross-linking macrophages to cancer cells.
- B Schematic of an exemplary anti-CD20 (and anti-SIRPa) BiME antibody.
- C Phagocytosis of Raji cells after exposure to a subject anti-CD20 (and anti-SIRPa) BiME antibody.
- Figures 5A-5B Demonstration of the bispecificity of the CD20 BiME by FACS. A.
- Binding of the CD20 BiME to yeast expressing hSIRPa was detected by an anti-human lgG4 Fc antibody conjugated to Alexa fluor-647 and an anti-rituximab antibody conjugated to FITC.
- B Binding of KWAR23 to yeast expressing hSIRPa was detected by the anti-human lgG4 Fc antibody but not the anti-rituximab antibody.
- Anti-SIRPa antibody (KWAR23) enhances ADCP and ADCC of cancer- targeting antibodies.
- Anti-SIRPa antibody enhances antibody-dependent cellular phagocytosis (ADCP) of cancer-targeting antibodies by human macrophages: A. KWAR23 + rituximab (anti-CD20) for human lymphoma cancer cells (Raji); B. KWAR23 + trastuzumab (anti-Her2) for human breast cancer cells (SKBR3); C. KWAR23 + vorsetuzumab (anti-CD70) for human renal cell cancer (RCC10, TK10, Cakil ). D-E. Anti-SIRPa antibody (KWAR23) enhances antibody-dependent cellular cytotoxicty (ADCC) of cancer-targeting antibodies by human neutrophils: D. KWAR23 + rituximab (anti-CD20) for human lymphoma cancer cells (Raji); E. KWAR23 + trastuzumab (anti-Her2) for human breast cancer cells (SKBR3).
- ADCP antibody-dependent cellular phagocytosis
- Bispecific macrophages enhancing antibodies enhance ADCP and ADCC compared to the parental cancer-targeting antibodies.
- A-C Anti-SIRPa antibody (KWAR23) BiMEs enhance antibody-dependent cellular phagocytosis (ADCP) of cancer- targeting antibodies by human macrophages: A. Anti-CD20 BiME (KWAR23 + rituximab (anti- CD20)) for human lymphoma cancer cells (Raji); B. Anti-Her2 BiME (KWAR23 + trastuzumab (anti-Her2)) for human breast cancer cells (SKBR3); C.
- Anti-CD70 BiME (KWAR23 + vorsetuzumab (anti-CD70)) for human renal cell cancer (RCC10, TK10, Cakil ).
- D. Anti-CD20 BiME (KWAR23 + rituximab (anti-CD20)) for human lymphoma cancer cells (Raji);
- Anti-Her2 BiME (KWAR23 + trastuzumab (anti-Her2)) for human breast cancer cells (SKBR3).
- FIG. 8 KWAR23 enhances phagocytosis in response to cetuximab in the presence of downstream mutations in the EGFR signaling pathway.
- FIG. 9 KWAR23 enhances phagocytosis in response to glycoengineered antibodies.
- the present disclosure relates to antibodies, including without limitation humanized monoclonal antibodies, that are specific for SIRPa. Also disclosed is a nucleic acid, and amino acid sequence of such antibodies. The antibodies find use in therapeutic and diagnostic methods associated with SIRPa.
- target cell can be used in different ways depending on context.
- a “target cell” is a cell that will be phagocytosed by a phagocytic cell (e.g., a phagocyte), where the phagocytosis is enhanced as a result of administering a subject anti-SIRPa antibody.
- the term “target cell” can refer to a CD47-expressing cell because a subject anti-SIRPa antibody, by inhibiting the interaction between the CD47-expressing cell and the SIRPa expressing phagocytic cell, facilitates phagocytosis of the CD47-expressing cell.
- the target cell need not express high levels of CD47 (and in some cases need not express CD47 at all) in order for a subject multispecific antibody to induce phagocytosis of the target cell.
- a subject multispecific (e.g., bispecific) antibody binds to SIRPa on a phagocytic cell (e.g., a macrophage), which allows the multispecific antibody to function as a tether to bring the phagocytic cell into the vicinity of a cell expressing an antigen (e.g., a marker of a cancer cell) that is recognized by (specifically bound by) a second binding region of the multispecific antibody (e.g., the second binding region of a bispecific antibody).
- an antigen e.g., a marker of a cancer cell
- a target cell in the context of a multispecific antibody, can be a cell that does not express high levels of CD47 (and can also be a cell that does not express CD47).
- a target cell is a mammalian cell, for example a human cell.
- a target cell can be from any individual (e.g., patient, subject, and the like) as described below.
- a target cell is an "inflicted” cell (e.g., a cell from an "inflicted” individual), where the term “inflicted” is used herein to refer to a subject with symptoms, an illness, or a disease that can be treated with a subject anti-SIRPa antibody.
- An “inflicted” subject can have cancer, can harbor an infection (e.g., a chronic infection), and/or can have other hyper- proliferative conditions, for example sclerosis, fibrosis, and the like, etc.
- “Inflicted cells” can be those cells that cause the symptoms, illness, or disease.
- the inflicted cells of an inflicted patient can be CD47 expressing cancer cells, infected cells, inflammatory cells, immune cells, and the like.
- One indication that an illness or disease can be treated with a subject anti-SI RPa antibody is that the involved cells (i.e., the inflicted cells, e.g., the cancerous cells, the infected cells, the inflammatory cells, the immune cells, etc.) express CD47 (e.g., in some cases, an increased level of CD47 compared to normal cells of the same cell type).
- treatment used herein to generally refer to obtaining a desired pharmacologic and/or physiologic effect.
- the effect can be prophylactic in terms of completely or partially preventing a disease or symptom(s) thereof and/or may be therapeutic in terms of a partial or complete stabilization or cure for a disease and/or adverse effect attributable to the disease.
- treatment encompasses any treatment of a disease in a mammal, particularly a human, and includes: (a) preventing the disease and/or symptom(s) from occurring in a subject who may be predisposed to the disease or symptom but has not yet been diagnosed as having it; (b) inhibiting the disease and/or symptom(s), i.e., arresting their development; or (c) relieving the disease symptom(s), i.e., causing regression of the disease and/or symptom(s).
- Those in need of treatment include those already inflicted (e.g., those with cancer, those with an infection, etc.) as well as those in which prevention is desired (e.g., those with increased susceptibility to cancer, those with an increased likelihood of infection, those suspected of having cancer, those suspected of harboring an infection, etc.).
- a therapeutic treatment is one in which the subject is inflicted prior to administration and a prophylactic treatment is one in which the subject is not inflicted prior to administration.
- the subject has an increased likelihood of becoming inflicted or is suspected of being inflicted prior to treatment.
- the subject is suspected of having an increased likelihood of becoming inflicted.
- Examples of symptoms, illnesses, and/or diseases that can be treated with a subject anti-SIRPa antibody include, but are not limited to cancer (any form of cancer, including but not limited to: carcinomas, soft tissue tumors, sarcomas, teratomas, melanomas, leukemias, lymphomas, brain cancers, solid tumors, mesothelioma (MSTO), etc.); infection (e.g., chronic infection); and an immunological disease or disorder (e.g., an inflammatory disease)(e.g., multiple sclerosis, arthritis, and the like)(e.g., for immunosuppressive therapy).
- cancer any form of cancer, including but not limited to: carcinomas, soft tissue tumors, sarcomas, teratomas, melanomas, leukemias, lymphomas, brain cancers, solid tumors, mesothelioma (MSTO), etc.
- infection e.g., chronic infection
- an immunological disease or disorder e.
- any cancer where the cancer cells express CD47 (e.g., in some cases, the cancer cells exhibit increased expression of CD47 compared to non-cancer cells), is a suitable cancer to be treated by the subject methods and compositions.
- a subject anti-SIRPa antibody can also be used for transplant conditioning (e.g., stem cell transplant, bone marrow transplant, etc.) (e.g., to destroy malignant cells, to provide immunosuppression to prevent the patient's body from rejecting the donor's cells/stem cells, etc.).
- transplant conditioning e.g., stem cell transplant, bone marrow transplant, etc.
- a subject antibody combination or bispecific antibody finds use for transplant conditioning.
- a subject antibody combination or bispecific antibody e.g., anti- SI RPa in combination with anti-CD1 17
- a subject anti-SIRPa antibody e.g., an antibody combination
- cancer includes any form of cancer, including but not limited to solid tumor cancers (e.g., lung, prostate, breast, bladder, colon, ovarian, pancreas, kidney, liver, glioblastoma, medulloblastoma, leiomyosarcoma, head & neck squamous cell carcinomas, melanomas, neuroendocrine; etc.) and liquid cancers (e.g., hematological cancers); carcinomas; soft tissue tumors; sarcomas; teratomas; melanomas; leukemias; lymphomas; and brain cancers, including minimal residual disease, and including both primary and metastatic tumors.
- solid tumor cancers e.g., lung, prostate, breast, bladder, colon, ovarian, pancreas, kidney, liver, glioblastoma, medulloblastoma, leiomyosarcoma, head & neck squamous cell carcinomas, melanomas, neuroendocrine; etc
- any cancer where the cancer cells express CD47 (e.g., in some cases, the cancer cells exhibit increased expression of CD47 compared to non-cancer cells), is a suitable cancer to be treated by the subject methods and compositions (e.g., a subject anti-SIRPa antibody).
- Carcinomas are malignancies that originate in the epithelial tissues. Epithelial cells cover the external surface of the body, line the internal cavities, and form the lining of glandular tissues. Examples of carcinomas include, but are not limited to: adenocarcinoma (cancer that begins in glandular (secretory) cells), e.g., cancers of the breast, pancreas, lung, prostate, and colon can be adenocarcinomas; adrenocortical carcinoma; hepatocellular carcinoma; renal cell carcinoma; ovarian carcinoma; carcinoma in situ; ductal carcinoma; carcinoma of the breast; basal cell carcinoma; squamous cell carcinoma; transitional cell carcinoma; colon carcinoma; nasopharyngeal carcinoma; multilocular cystic renal cell carcinoma; oat cell carcinoma; large cell lung carcinoma; small cell lung carcinoma; non-small cell lung carcinoma; and the like. Carcinomas may be found in prostrate, pancreas, colon, brain (usually as secondary metastases), lung, breast,
- Soft tissue tumors are a highly diverse group of rare tumors that are derived from connective tissue.
- soft tissue tumors include, but are not limited to: alveolar soft part sarcoma; angiomatoid fibrous histiocytoma; chondromyoxid fibroma; skeletal chondrosarcoma; extraskeletal myxoid chondrosarcoma; clear cell sarcoma; desmoplastic small round-cell tumor; dermatofibrosarcoma protuberans; endometrial stromal tumor; Ewing's sarcoma; fibromatosis (Desmoid); fibrosarcoma, infantile; gastrointestinal stromal tumor; bone giant cell tumor; tenosynovial giant cell tumor; inflammatory myofibroblastic tumor; uterine leiomyoma; leiomyosarcoma; lipoblastoma; typical lipoma; spindle cell or pleomorphic lipoma; a
- a sarcoma is a rare type of cancer that arises in cells of mesenchymal origin, e.g., in bone or in the soft tissues of the body, including cartilage, fat, muscle, blood vessels, fibrous tissue, or other connective or supportive tissue.
- Different types of sarcoma are based on where the cancer forms. For example, osteosarcoma forms in bone, liposarcoma forms in fat, and rhabdomyosarcoma forms in muscle.
- sarcomas include, but are not limited to: askin's tumor; sarcoma botryoides; chondrosarcoma; ewing's sarcoma; malignant hemangioendothelioma; malignant schwannoma; osteosarcoma; and soft tissue sarcomas (e.g., alveolar soft part sarcoma; angiosarcoma; cystosarcoma phyllodesdermatofibrosarcoma protuberans (DFSP); desmoid tumor; desmoplastic small round cell tumor; epithelioid sarcoma; extraskeletal chondrosarcoma; extraskeletal osteosarcoma; fibrosarcoma; gastrointestinal stromal tumor (GIST); hemangiopericytoma; hemangiosarcoma (more commonly referred to as "angiosarcoma”); kaposi's sarcoma; leiomyosarcoma; lipos
- a teratomas is a type of germ cell tumor that may contain several different types of tissue (e.g., can include tissues derived from any and/or all of the three germ layers: endoderm, mesoderm, and ectoderm), including for example, hair, muscle, and bone. Teratomas occur most often in the ovaries in women, the testicles in men, and the tailbone in children.
- Melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.
- Leukemias are cancers that start in blood-forming tissue, such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the bloodstream.
- leukemias can originate in bone marrow-derived cells that normally mature in the bloodstream.
- Leukemias are named for how quickly the disease develops and progresses (e.g., acute versus chronic) and for the type of white blood cell that is effected (e.g., myeloid versus lymphoid).
- Myeloid leukemias are also called myelogenous or myeloblasts leukemias.
- Lymphoid leukemias are also called lymphoblastic or lymphocytic leukemia.
- Lymphoid leukemia cells may collect in the lymph nodes, which can become swollen.
- leukemias include, but are not limited to: Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML), and Chronic lymphocytic leukemia (CLL).
- Lymphomas are cancers that begin in cells of the immune system.
- lymphomas can originate in bone marrow-derived cells that normally mature in the lymphatic system.
- One kind is Hodgkin lymphoma (HL), which is marked by the presence of a type of cell called the Reed-Sternberg cell.
- HL Hodgkin lymphoma
- Examples of Hodgkin lymphomas include: nodular sclerosis classical Hodgkin lymphoma (CHL), mixed cellularity CHL, lymphocyte-depletion CHL, lymphocyte-rich CHL, and nodular lymphocyte predominant HL
- NHL non-Hodgkin lymphomas
- non-Hodgkin lymphomas include, but are not limited to: AIDS-related Lymphomas, anaplastic large-cell lymphoma, angioimmunoblastic lymphoma, blastic NK-cell lymphoma, Burkitt's lymphoma, Burkitt-like lymphoma (small non-cleaved cell lymphoma), chronic lymphocytic leukemia/small lymphocytic lymphoma, cutaneous T-Cell lymphoma, diffuse large B-Cell lymphoma, enteropathy-type T-Cell lymphoma, follicular lymphoma, hepatosplenic gamma- delta T-Cell lymphomas, T-Cell leukemias, lymphoblastic lymphoma, mantle cell lymphoma, marginal zone lymphoma, nasal T-Cell lymphoma, pediatric lymphoma, peripheral T-Cell lymphomas, primary central nervous system lymphoma, transformed lymphomas,
- Brain cancers include any cancer of the brain tissues.
- Examples of brain cancers include, but are not limited to: gliomas (e.g., glioblastomas, astrocytomas, oligodendrogliomas, ependymomas, and the like), meningiomas, pituitary adenomas, vestibular schwannomas, primitive neuroectodermal tumors (medulloblastomas), etc.
- the term "infection” refers to any state in at least one cell of an organism (i.e., a subject) is infected by an infectious agent (e.g., a subject has an intracellular pathogen infection, e.g., a chronic intracellular pathogen infection).
- infectious agent refers to a foreign biological entity (i.e. a pathogen) that induces CD47 expression (e.g., increased CD47 expression) in at least one cell of the infected organism.
- infectious agents include, but are not limited to bacteria, viruses, protozoans, and fungi.
- Intracellular pathogens are of particular interest. Infectious diseases are disorders caused by infectious agents.
- infectious agents cause no recognizable symptoms or disease under certain conditions, but have the potential to cause symptoms or disease under changed conditions.
- the subject methods can be used in the treatment of chronic pathogen infections, for example including but not limited to viral infections, e.g. retrovirus, lentivirus, hepadna virus, herpes viruses, pox viruses, human papilloma viruses, eic; intracellular bacterial infections, e.g. Mycobacterium, Chlamydophila, Ehrlichia, Rickettsia, Brucella, Legionella, Francisella, Listeria, Coxiella, Neisseria, Salmonella, Yersinia sp, Helicobacter pylori etc.; and intracellular protozoan pathogens, e.g. Plasmodium sp, Trypanosoma sp., Giardia sp., Toxoplasma sp., Leishmania sp., etc.
- viral infections e.g. retrovirus, lent
- the terms "recipient”, “individual”, “subject”, “host”, and “patient”, are used interchangeably herein and refer to any mammalian subject for whom diagnosis, treatment, or therapy is desired, particularly humans.
- "Mammal” for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, sheep, goats, pigs, etc.
- the mammal is human.
- epitopic determinants means any antigenic determinant on an antigen to which the paratope of an antibody binds.
- Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
- antibody is used in the broadest sense and specifically covers monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired biological activity.
- Antibodies (Abs) and “immunoglobulins” (Igs) are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules which lack antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas.
- antibody refers to a polypeptide that includes canonical immunoglobulin sequence elements sufficient to confer specific binding to a particular target antigen.
- intact antibodies as produced in nature are approximately 150 kD tetrameric agents comprised of two identical heavy chain polypeptides (about 50 kD each) and two identical light chain polypeptides (about 25 kD each) that associate with each other into what is commonly referred to as a ⁇ -shaped" structure.
- Each heavy chain is comprised of at least four domains (each about 1 10 amino acids long)- an amino-terminal variable (VH) domain (located at the tips of the Y structure), followed by three constant domains: CH1 , CH2, and the carboxy-terminal CH3 (located at the base of the Y's stem).
- VH amino-terminal variable
- CH1 , CH2 and CH3 located at the base of the Y's stem.
- a short region known as the "switch” connects the heavy chain variable and constant regions.
- the “hinge” connects CH2 and CH3 domains to the rest of the antibody. Two disulfide bonds in this hinge region connect the two heavy chain polypeptides to one another in an intact antibody.
- Each light chain is comprised of two domains - an amino-terminal variable (VL) domain, followed by a carboxy- terminal constant (CL) domain, separated from one another by another "switch".
- Intact antibody tetramers are comprised of two heavy chain-light chain dimers in which the heavy and light chains are linked to one another by a single disulfide bond; two other disulfide bonds connect the heavy chain hinge regions to one another, so that the dimers are connected to one another and the tetramer is formed.
- Naturally-produced antibodies are also glycosylated, typically on the CH2 domain.
- Each domain in a natural antibody has a structure characterized by an "immunoglobulin fold" formed from two beta sheets (e.g., 3-, 4-, or 5-stranded sheets) packed against each other in a compressed antiparallel beta barrel.
- Each variable domain contains three hypervariable loops known as “complement determining regions” (CDR1 , CDR2, and CDR3) and four somewhat invariant "framework” regions (FR1 , FR2, FR3, and FR4).
- the Fc region of naturally-occurring antibodies binds to elements of the complement system, and also to receptors on effector cells, including for example effector cells that mediate cytotoxicity, including specifically ADCP.
- affinity and/or other binding attributes of Fc regions for Fc receptors can be modulated through glycosylation or other modification.
- antibodies produced and/or utilized in accordance with the present invention include glycosylated Fc domains, including Fc domains with modified or engineered such glycosylation.
- any polypeptide or complex of polypeptides that includes sufficient immunoglobulin domain sequences as found in natural antibodies can be referred to and/or used as an "antibody", whether such polypeptide is naturally produced (e.g., generated by an organism reacting to an antigen), or produced by recombinant engineering, chemical synthesis, or other artificial system or methodology.
- an antibody is polyclonal; in some embodiments, an antibody is monoclonal.
- an antibody has constant region sequences that are characteristic of mouse, rabbit, primate, or human antibodies.
- antibody sequence elements are humanized, primatized, chimeric, etc, as is known in the art.
- an antibody utilized in accordance with the present invention is in a format selected from, but not limited to, intact IgG, IgE and IgM, bi- or multi- specific antibodies (e.g., Zybodies®, etc), single chain Fvs, polypeptide-Fc fusions, Fabs, cameloid antibodies, masked antibodies (e.g., Probodies®), Small Modular ImmunoPharmaceuticals (“SMIPsTM ), single chain or Tandem diabodies (TandAb®), VHHs, Anticalins®, Nanobodies®, minibodies, BiTE®s, ankyrin repeat proteins or DARPINs®, Avimers®, a DART, a TCR-like antibody, Adnectins®, Affil
- an antibody may lack a covalent modification (e.g., attachment of a glycan) that it would have if produced naturally.
- an antibody may contain a covalent modification (e.g., attachment of a glycan, a payload, e.g., a detectable moiety, a therapeutic moiety, a catalytic moiety, etc., or other pendant group [e.g., poly-ethylene glycol, etc.
- Exemplary antibody agents include, but are not limited to, human antibodies, primatized antibodies, chimeric antibodies, bi-specific antibodies, humanized antibodies, conjugated antibodies (i.e., antibodies conjugated or fused to other proteins, radiolabels, cytotoxins), Small Modular immunoPharmaceuticals ("SMIPsTM ), single chain antibodies, cameloid antibodies, and antibody fragments.
- antibody agent also includes intact monoclonal antibodies, polyclonal antibodies, single domain antibodies (e.g., shark single domain antibodies (e.g., IgNAR or fragments thereof)), multispecific antibodies (e.g. bi-specific antibodies) formed from at least two intact antibodies, and antibody fragments so long as they exhibit the desired biological activity.
- the term encompasses stapled peptides. In some embodiments, the term encompasses one or more antibody-like binding peptidomimetics. In some embodiments, the term encompasses one or more antibody-like binding scaffold proteins. In come embodiments, the term encompasses monobodies or adnectins.
- an antibody agent is or comprises a polypeptide whose amino acid sequence includes one or more structural elements recognized by those skilled in the art as a complementarity determining region (CDR); in some embodiments an antibody agent is or comprises a polypeptide whose amino acid sequence includes at least one CDR (e.g., at least one heavy chain CDR and/or at least one light chain CDR) that is substantially identical to one found in a reference antibody. In some embodiments an included CDR is substantially identical to a reference CDR in that it is either identical in sequence or contains between 1 -5 amino acid substitutions as compared with the reference CDR.
- CDR complementarity determining region
- an included CDR is substantially identical to a reference CDR in that it shows at least 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that it shows at least 96%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDR.
- an included CDR is substantially identical to a reference CDR in that at least one amino acid within the included CDR is deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical with that of the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that 1 -5 amino acids within the included CDR are deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical to the reference CDR.
- an included CDR is substantially identical to a reference CDR in that at least one amino acid within the included CDR is substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical with that of the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that 1 -5 amino acids within the included CDR are deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical to the reference CDR.
- an antibody agent is or comprises a polypeptide whose amino acid sequence includes structural elements recognized by those skilled in the art as an immunoglobulin variable domain. In some embodiments, an antibody agent is a polypeptide protein having a binding domain which is homologous or largely homologous to an immunoglobulin-binding domain.
- “Native antibodies and immunoglobulins” are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (V H ) followed by a number of constant domains.
- V H variable domain
- Each light chain has a variable domain at one end (V L ) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain.
- Particular amino acid residues are believed to form an interface between the light- and heavy-chain variable domains (Clothia et al., J. Mol. Biol. 186:651 (1985); Novotny and Haber, Proc. Natl. Acad. Sci. U.S.A. 82:4592 (1985)).
- variable refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions both in the light-chain and the heavy-chain variable domains. The more highly conserved portions of variable domains are called the framework (FR).
- CDRs complementarity-determining regions
- FR framework
- the variable domains of native heavy and light chains each comprise four FR regions, largely adopting a b-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the b-sheet structure.
- the CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991 )).
- the constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.
- Variable region sequences of interest include the provided variable region sequences for the anti-SIRPa antibody referred to herein as "KWAR23": SEQ ID NO: 1 (variable heavy chain), and SEQ ID NO: 5 (variable light chain).
- the KWAR23 CDR sequences are set forth in the sequence listing, including SEQ ID NOs: 2-4 (CDRs of the variable heavy chain); and SEQ ID NOs: 6-8 (CDRs of the variable light chain).
- the CDR sequences for a particularly heavy and light chain combination as set forth in KWAR23 will be maintained in a combination, i.e. a subject antibody (e.g., a humanized antibody) will comprise both KWAR23 heavy chain CDR sequences and KWAR23 light chain CDR sequences.
- Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual "Fc” fragment, whose name reflects its ability to crystallize readily.
- Pepsin treatment yields an F(ab') 2 fragment that has two antigen-combining sites and is still capable of cross-linking antigen.
- Fv is the minimum antibody fragment which contains a complete antigen-recognition and -binding site.
- this region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association.
- scFv single-chain Fv species
- one heavy- and one light-chain variable domain can be covalently linked by a flexible peptide linker such that the light and heavy chains can associate in a "dimeric" structure analogous to that in a two-chain Fv species. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer.
- the Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1 ) of the heavy chain.
- Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region.
- Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group.
- F(ab') 2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
- immunoglobulins There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these can be further divided into subclasses (isotypes), e.g., IgG ⁇ lgG 2 , lgG 3 , lgG 4 , IgA-i , lgA 2 .
- the heavy-chain constant domains that correspond to the different classes of immunoglobulins are called a, d, e, g, and m, respectively.
- the subunit structures and three- dimensional configurations of different classes of immunoglobulins are well known. Engineered variants of immunoglobulin subclasses, including those that increase or decrease immune effector functions, half-life, or serum-stability, are also encompassed by this terminology.
- Antibody fragment and all grammatical variants thereof, as used herein are defined as a portion of an intact antibody comprising the antigen binding site or variable region of the intact antibody, wherein the portion is free of the constant heavy chain domains (i.e. CH2, CH3, and CH4, depending on antibody isotype) of the Fc region of the intact antibody.
- constant heavy chain domains i.e. CH2, CH3, and CH4, depending on antibody isotype
- antibody fragments include Fab, Fab', Fab'-SH, F(ab') 2 , and Fv fragments; diabodies; any antibody fragment that is a polypeptide having a primary structure consisting of one uninterrupted sequence of contiguous amino acid residues (referred to herein as a "single-chain antibody fragment” or “single chain polypeptide"), including without limitation (1 ) single-chain Fv (scFv) molecules (2) single chain polypeptides containing only one light chain variable domain, or a fragment thereof that contains the three CDRs of the light chain variable domain, without an associated heavy chain moiety and (3) single chain polypeptides containing only one heavy chain variable region, or a fragment thereof containing the three CDRs of the heavy chain variable region, without an associated light chain moiety; and multispecific or multivalent structures formed from antibody fragments.
- scFv single-chain Fv
- the heavy chain(s) can contain any constant domain sequence (e.g. CH1 in the IgG isotype) found in a non-Fc region of an intact antibody, and/or can contain any hinge region sequence found in an intact antibody, and/or can contain a leucine zipper sequence fused to or situated in the hinge region sequence or the constant domain sequence of the heavy chain(s).
- any constant domain sequence e.g. CH1 in the IgG isotype
- conjugate is defined as a heterogeneous molecule formed by the covalent attachment of one or more antibody fragment(s) to one or more polymer molecule(s), wherein the heterogeneous molecule is water soluble, i.e. soluble in physiological fluids such as blood, and wherein the heterogeneous molecule is free of any structured aggregate.
- a conjugate of interest is PEG.
- structured aggregate refers to (1 ) any aggregate of molecules in aqueous solution having a spheroid or spheroid shell structure, such that the heterogeneous molecule is not in a micelle or other emulsion structure, and is not anchored to a lipid bilayer, vesicle or liposome; and (2) any aggregate of molecules in solid or insolubilized form, such as a chromatography bead matrix, that does not release the heterogeneous molecule into solution upon contact with an aqueous phase.
- conjugate encompasses the aforementioned heterogeneous molecule in a precipitate, sediment, bioerodible matrix or other solid capable of releasing the heterogeneous molecule into aqueous solution upon hydration of the solid.
- mAb monoclonal antibody
- monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts.
- Monoclonal antibodies are highly specific, being directed against a single antigenic site. Each mAb is directed against a single determinant on the antigen.
- the monoclonal antibodies are advantageous in that they can be synthesized by hybridoma culture, uncontaminated by other immunoglobulins.
- the modifier "monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
- the monoclonal antibodies to be used in accordance with the present invention may be made in an immortalized B cell or hybridoma thereof, or may be made by recombinant DNA methods.
- the anti-SIRPa antibodies herein include hybrid and recombinant antibodies produced by splicing a variable (including hypervariable) domain of an anti-SIRPa antibody with a constant domain (e.g. "humanized” antibodies), or a light chain with a heavy chain, or a chain from one species with a chain from another species, or fusions with heterologous proteins, regardless of species of origin or immunoglobulin class or subclass designation, as well as antibody fragments (e.g., Fab, F(ab') 2 , and Fv), so long as they exhibit the desired biological activity.
- the anti-SI RPa antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.
- chimeric antibodies immunoglobulins in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.
- an "isolated" antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.
- the antibody will be purified (1 ) to greater than 75% by weight of antibody as determined by the Lowry method, and most preferably more than 80%, 90% or 99% by weight, or (2) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain.
- Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
- epitope tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the anti-SIRPa antibody.
- the epitope tag preferably is sufficiently unique so that the antibody specific for the epitope does not substantially cross- react with other epitopes.
- Suitable tag polypeptides generally have at least 6 amino acid residues and usually between about 8-50 amino acid residues (preferably between about 9-30 residues).
- Examples include the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto (Evan et al., Mol. Cell. Biol. 5(12):3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky et al., Protein Engineering 3(6):547-553 (1990)).
- An additional example is a "histidine tag” or "histidine-rich affinity peptide", which is a metal ion affinity peptide that is rich in histidines (e.g., 6xHis tag, HAT tag, 6xHN tag, and the like).
- a histidine tag can also specifically bind to an anti-His antibody.
- label when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody.
- the label may itself be detectable by itself (e.g., radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.
- solid phase is meant a non-aqueous matrix to which the antibody of the present invention can adhere.
- solid phases encompassed herein include those formed partially or entirely of glass (e.g. controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones.
- the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g. an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Pat. No. 4,275,149.
- binding refers to non-covalent or covalent preferential binding to a molecule relative to other molecules or moieties in a solution or reaction mixture (e.g., an antibody specifically binds to a particular polypeptide or epitope relative to other available polypeptides).
- the affinity of one molecule for another molecule to which it specifically binds is characterized by a K d (dissociation constant) of 10 "5 M or less (e.g., 10 "6 M or less, 10 "7 M or less, 10 “8 M or less, 10 "9 M or less, 10 "10 M or less, 10 "11 M or less, 10 "12 M or less, 10 “13 M or less, 10 “14 M or less, 10 "15 M or less, or 10 "16 M or less).
- K d dissociation constant
- specific binding member refers to a member of a specific binding pair (i.e., two molecules, usually two different molecules, where one of the molecules, e.g., a first specific binding member, through non-covalent means specifically binds to the other molecule, e.g., a second specific binding member).
- co-administration include the administration of two or more therapeutic agents either simultaneously, concurrently or sequentially within no specific time limits.
- the agents are present in the cell or in the subject's body at the same time or exert their biological or therapeutic effect at the same time.
- the therapeutic agents are in the same composition or unit dosage form. In other embodiments, the therapeutic agents are in separate compositions or unit dosage forms.
- a first agent can be administered prior to (e.g., minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second therapeutic agent.
- the present disclosure is directed to antibodies (and cell lines that produce such antibodies) that specifically bind human SIRPa (i.e., an anti-SIRPa antibody) and reduce the interaction between CD47 on one cell (e.g., a cancerous cell, an infected cell, etc.) and SIRPa on another cell (e.g., a phagocytic cell).
- subject anti-SIRPa antibodies can bind SI RPa without inhibiting phagocytosis (activating or stimulating signaling through SIRPa inhibits phagocytosis).
- subject anti-SIRPa antibodies can bind SIRPa without activating or stimulating signaling through SIRPa (e.g., a subject anti-SIRPa antibody does not stimulate SI RPa signaling to a level that inhibits phagocytosis).
- subject anti-SIRPa antibodies can bind SIRPa, but block CD47-induced SIRPa signaling.
- suitable anti- SIRPa antibodies facilitate the preferential phagocytosis of inflicted cells (e.g., cancerous cells, infected cells, etc.) over normal cells by inhibiting CD47-induced SIRPa signaling.
- a suitable anti-SIRPa antibody specifically binds SIRPa (without activating/stimulating enough of a signaling response to inhibit phagocytosis) and blocks an interaction between SIRPa and CD47.
- Suitable anti-SIRPa antibodies include fully human, humanized or chimeric versions of such antibodies. Humanized antibodies are especially useful for in vivo applications in humans due to their low antigenicity. Similarly caninized, felinized, etc. antibodies are especially useful for applications in dogs, cats, and other species respectively.
- Antibodies of interest include humanized antibodies, or caninized, felinized, equinized, bovinized, porcinized, etc., antibodies, and variants thereof.
- Variable regions of exemplary antibodies are provided. Antibodies of interest include these provided combinations, as well as fusions of the variable regions to appropriate constant regions or fragments of constant regions, e.g. to generate F(ab)' antibodies. Variable regions of interest include at least one CDR sequence of the provided anti-SI RPa antibody, where a CDR may be 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12 or more amino acids. Alternatively, antibodies of interest include a variable region as set forth in the provided antibodies, or pairs of variable regions sequences as set forth herein.
- Polypeptides of interest can include an amino acid sequence that is 80% or more, 85% or more, 90% or more, 92% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% identical to an amino acid sequence set forth in any of SEQ ID NOs: 1-18.
- a subject anti-SI RPa antibody may include: (i) one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, or 6 or more) CDR sequences (e.g., those set forth in SEQ ID NOs: 2-4 and 6-8); (ii) a complete variable region (e.g., those set forth in SEQ ID NOs: 1 and 5); (iii) single- chain variable fragments (e.g., those set forth in SEQ ID NOs: 9-10); (iv) chimeric antibody sequences (e.g., those set forth in SEQ ID NOs: 1 1-12); and/or (v) bispecific antibody sequences (e.g., those set forth in SEQ ID NOs: 13-18).
- a variable region sequence may be fused to any appropriate constant region sequence.
- a subject anti-SIRPa antibody includes one more CDRs (e.g., 2 or more, 3 or more, 4 or more, 5 or more, or 6 CDRs) that includes an amino acid sequence set forth in SEQ ID NOs: 2-4 and 6-8.
- a subject anti-SIRPa antibody can include a CDR sequence that differs by up to 6 amino acids (e.g., up to 5 amino acids, up to 4 amino acids, up to 3 amino acids, up to 2 amino acids, or up to 1 amino acid) as compared to a CDR amino acid sequence set forth in any of SEQ ID NOs: 2-4 and 6-8.
- a subject anti-SIRPa antibody includes one or more CDRs (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6, or 6 or more) having an amino acid sequence that differs by up to 6 amino acids (e.g., up to 5 amino acids, up to 4 amino acids, up to 3 amino acids, up to 2 amino acids, or up to 1 amino acid) as compared to a CDR amino acid sequence set forth in any of SEQ ID NOs: 2-4 and 6-8.
- CDRs e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6, or 6 or more
- a subject anti-SIRPa antibody includes two or more CDRs (e.g., 3 or more, 4 or more, 5 or more, 6, or 6 or more) that have an amino acid sequence that differs by up to 6 amino acids (e.g., up to 5 amino acids, up to 4 amino acids, up to 3 amino acids, up to 2 amino acids, or up to 1 amino acid) as compared to a CDR amino acid sequence set forth in any of SEQ ID NOs: 2-4 and 6-8.
- up to 6 amino acids e.g., up to 5 amino acids, up to 4 amino acids, up to 3 amino acids, up to 2 amino acids, or up to 1 amino acid
- a subject anti-SIRPa antibody includes an amino acid sequence that is 80% or more, 85% or more, 90% or more, 92% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% identical to a CDR amino acid sequence set forth in any of SEQ ID NOs: 2-4 and 6-8.
- a subject anti-SIRPa antibody includes a heavy chain having one or more (e.g., two or more, three or more, or 3) of the amino acid sequences set forth in SEQ ID NOs: 2-4.
- a subject anti-SIRPa antibody includes a heavy chain having all 3 of the amino acid sequences set forth in SEQ ID NOs: 2-4. In some cases, a subject anti-SIRPa antibody includes a light chain having one or more (e.g., two or more, three or more, or 3) of the amino acid sequences set forth in SEQ ID NOs: 6-8. In some cases, a subject anti-SIRPa antibody includes a light chain having all 3 of the amino acid sequences set forth in SEQ ID NOs: 6-8.
- a subject anti-SIRPa antibody includes a light chain having all 3 of the amino acid sequences set forth in SEQ ID NOs: 6-8, and a heavy chain having all 3 of the amino acid sequences set forth in SEQ ID NOs: 2-4.
- a subject anti-SI RPa antibody includes a heavy chain having three CDRs, where CDR-H1 has the amino acid sequence set forth in SEQ ID NO: 2, CDR-H2 has the amino acid sequence set forth in SEQ ID NO: 3, and CDR-H3 has the amino acid sequence set forth in SEQ ID NO: 4.
- a subject anti-SIRPa antibody includes a light chain having three CDRs, where CDR-L1 has the amino acid sequence set forth in SEQ ID NO: 6, CDR-L2 has the amino acid sequence set forth in SEQ ID NO: 7, and CDR-L3 has the amino acid sequence set forth in SEQ ID NO: 8.
- a subject anti-SIRPa antibody includes: (i) a heavy chain having three CDRs, where CDR-H1 has the amino acid sequence set forth in SEQ ID NO: 2, CDR-H2 has the amino acid sequence set forth in SEQ ID NO: 3, and CDR-H3 has the amino acid sequence set forth in SEQ ID NO: 4; and (ii) a light chain having three CDRs, where CDR-L1 has the amino acid sequence set forth in SEQ ID NO: 6, CDR-L2 has the amino acid sequence set forth in SEQ ID NO: 7, and CDR-L3 has the amino acid sequence set forth in SEQ ID NO: 8.
- a subject anti-SIRPa antibody includes a heavy chain having an amino acid sequence as set forth in any one of SEQ ID NOs: 9-10, which are examples of single-chain variable fragments. In some cases, a subject anti-SIRPa antibody includes a heavy chain having an amino acid sequence as set forth in any one of SEQ ID NOs: 1 , 1 1 , 13, 15, and 17. In some cases, a subject anti-SIRPa antibody includes a light chain having an amino acid sequence as set forth in any one of SEQ ID NOs: 5, 12, 14, 16, and 18.
- a subject anti-SIRPa antibody includes a heavy chain having an amino acid sequence as set forth in any one of SEQ I D NOs: 1 , 1 1 , 13, 15, and 17; and a light chain having an amino acid sequence as set forth in any one of SEQ ID NOs: 5, 12, 14, 16, and 18.
- a subject anti-SI RPa antibody includes a heavy chain having the amino acid sequence of SEQ ID NO: 1 , and a light chain having the amino acid sequence of SEQ ID NO: 5. In some cases, a subject anti-SIRPa antibody includes a heavy chain having the amino acid sequence of SEQ ID NO: 1 1 , and a light chain having the amino acid sequence of SEQ ID NO: 12. In some cases, a subject anti-SIRPa antibody includes a heavy chain having the amino acid sequence of SEQ ID NO: 13, and a light chain having the amino acid sequence of SEQ ID NO: 14.
- a subject anti-SIRPa antibody includes a heavy chain having the amino acid sequence of SEQ ID NO: 15, and a light chain having the amino acid sequence of SEQ ID NO: 16. In some cases, a subject anti-SIRPa antibody includes a heavy chain having the amino acid sequence of SEQ ID NO: 17, and a light chain having the amino acid sequence of SEQ ID NO: 18.
- a subject antibody is a bispecific antibody.
- multispecific or bispecific antibodies also known as bifunctional antibodies or multifunctional antibodies refer to antibodies that recognize two or more different antigens by virtue of possessing at least one region (e.g., derived from a variable region of a first antibody) that is specific for a first antigen, and at least a second region (e.g., derived from a variable region of a second antibody) that is specific for a second antigen.
- a bispecific antibody specifically binds to two target antigens and is thus one type of multispecific antibody.
- Multispecific antibodies can be produced by recombinant DNA methods or include, but are not limited to, antibodies produced chemically by any convenient method.
- Bispecific antibodies include all antibodies or conjugates of antibodies, or polymeric forms of antibodies which are capable of recognizing two different antigens.
- Bispecific antibodies include antibodies that have been reduced and reformed so as to retain their bivalent characteristics and to antibodies that have been chemically coupled so that they can have several antigen recognition sites for each antigen.
- the SIRPa binding region (the first binding region) of a subject multispecific (e.g., bispecific) antibody binds to SIRPa on a macrophage and the multispecific antibody thereby functions as a tether to bring the SIRPa-expressing phagocytic cell into the vacinity of a cell that expresses the antigen that is recognized by (specifically bound by) a second binding region of the multispecific antibody (e.g., the second binding region of a bispecific antibody).
- the target cell need not express high levels of CD47 (and in some cases need not express CD47 at all) in order for a subject multispecific antibody to induce phagocytosis of the target cell.
- an Fc region of a multispecific antibody can be recognized by the phagocytic cell (see Figure 4).
- a subject multispecific (e.g, bispecific) antibody includes a pro-phagocytic antibody Fc chain.
- Subject bispecific antibodies are directed against SIRPa and a second antigen.
- Subject bispecific antibodies will allow for the phagocytosis of cellular populations expressing the second antigen (see Figure 4).
- Exemplary bispecific antibodies include those targeting a combination of SIRPa and a cancer cell marker, such as, CD19, CD20, CD22, CD24, CD25, CD30, CD33, CD38, CD44, CD52, CD56, CD70, CD96, CD97, CD99, CD123, CD279 (PD-1 ), EGFR, HER2, CD1 17, C-Met, PTHR2, HAVCR2 (TIM3), etc.
- a subject antibody is a bispecific or multispecific antibody that specifically binds to SIRPa and at least a second antigen.
- the second antigen is selected from: CD19, CD20, CD22, CD24, CD25, CD30, CD33, CD38, CD44, CD52, CD56, CD70, CD96, CD97, CD99, CD123, CD279 (PD-1 ), EGFR, HER2, CD1 17, C-Met, PTHR2, HAVCR2 (TIM3).
- an exemplary bispecific antibody includes a sequence (e.g., CDRs) disclosed herein that provides specific binding to SIRPa as well as sequences (e.g., CDRs) from antibodies that bind a cancer cell marker.
- CDRs sequences that provide specific binding to a cancer cell marker.
- antibodies with CDRs that provide specific binding to a cancer cell marker include, but are not limited to: CETUXIMAB (binds EGFR), PANITUMUMAB (binds EGFR), RITUXIMAB (binds CD20), TRASTUZUMAB (binds HER2), PERTUZUMAB (binds HER2), ALEMTUZUMAB (binds CD52), BRENTUXIMAB (binds CD30), and the like.
- the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture.
- Such interfaces may comprise at least a part of the CH 3 domain of an antibody constant domain.
- one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan).
- Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g., alanine or threonine).
- HSA heat stable antigen
- Bispecific antibodies include cross-linked or "heteroconjugate" antibodies.
- one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin.
- Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO 91/00360, WO 92/200373, and EP 03089).
- Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Pat. No. 4,676,980, along with a number of cross-linking techniques.
- bispecific antibodies can be prepared using chemical linkage.
- Brennan et al., Science, 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab') 2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation.
- the Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives.
- One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody.
- the bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.
- bispecific antibodies have been produced using leucine zippers.
- the leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion.
- the antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers.
- the "diabody” technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments.
- the fragments comprise a heavy-chain variable domain (V H ) connected to a light- chain variable domain (V L ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V H and V L domains of one fragment are forced to pair with the complementary V L and V H domains of another fragment, thereby forming two antigen-binding sites.
- Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported.
- the antibodies can be "linear antibodies" as described in Zapata et al. Protein Eng. 8(10): 1057-1062 (1995). Briefly, these antibodies comprise a pair of tandem Fd segments (V H -C H r V H -C H 1 ) which form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.
- Dual variable domain (DVD) bispecific antibodies and methods to generate them have also been described (e.g., see Wu et al., Nat Biotechnol. 2007 Nov;25(1 1 ):1290-7, Gu et al., Methods Enzymol. 2012;502:25-41 , and U.S.
- the target-binding variable domains of two polypeptides can be combined via linkers to create a tetravalent, multi-targeting (e.g., dual-targeting) single agent (bispecific and/or multispecific antibody).
- the produced agent can be a dual-specific, tetravalent immunoglobulin G (IgG)-like molecule, termed dual-variable-domain immunoglobulin (DVD-lg), that can be engineered from any two antibodies (e.g., monoclonal antibodies) while preserving activities of the parental antibodies.
- IgG immunoglobulin G
- DVD-lg dual-variable-domain immunoglobulin
- This type of molecule can be efficiently produced from mammalian cells and exhibits good physicochemical and pharmacokinetic properties.
- antibodies are understood to include monoclonal antibodies and polyclonal antibodies, antibody fragments (e.g., Fab and F(ab') 2 ), chimeric antibodies bifunctional or bispecific antibodies and tetrameric antibody complexes.
- Antibodies of the present disclosure may also be described or specified in terms of their binding affinities, including those characterized by a K d (dissociation constant) of 10 "5 M or less (e.g., 10 "6 M or less, 10 "7 M or less, 10 “8 M or less, 10 "9 M or less, 10 "10 M or less, 10 "11 M or less, 10 "12 M or less, 10 "13 M or less, 10 “14 M or less, 10 "15 M or less, or 10 "16 M or less).
- K d dissociation constant
- each antigen-specific region can have a K d (dissociation constant) of 10 "5 M or less (e.g., 10 "6 M or less, 10 "7 M or less, 10 “8 M or less, 10 "9 M or less, 10 "10 M or less, 10 "11 M or less, 10 "12 M or less, 10 "13 M or less, 10 "14 M or less, 10 "15 M or less, or 10 "16 M or less).
- K d dissociation constant
- single chain antibodies can be constructed according to the method of U.S. Pat. No. 4,946,778 to Ladner et al, which is incorporated herein by reference in its entirety.
- Single chain antibodies can include the variable regions of the light and heavy chains joined by a flexible linker moiety.
- Exemplary suitable single chain antibodies can include an amino acid sequence set forth herein (e.g., SEQ ID NOs: 2-4, 6-8, and/or 9-10) (SEQ ID NOs: 2-4 and 6-8 are CDRs) (SEQ ID NO: 9 is KWAR23 scFv Heavy-Light) (SEQ ID NO: 10 is KWAR23 scFv Light-Heavy).
- the antibody fragment known as the single domain antibody, which comprises an isolate VH single domain.
- Techniques for obtaining a single domain antibody with at least some of the binding specificity of the intact antibody from which they are derived are known in the art. For instance, Ward, et al. in "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from Escherichia coli," Nature 341 : 644-646, disclose a method for screening to obtain an antibody heavy chain variable region (H single domain antibody) with sufficient affinity for its target epitope to bind thereto in isolate form.
- the disclosure also provides isolated nucleic acids encoding subject anti-SIRPa antibodies (e.g., including any of the polypeptides discussed above), vectors and host cells comprising the nucleic acid, and recombinant techniques for the production of the antibody.
- Nucleic acids of interest may encode an amino acid sequence that is 80% or more, 85% or more, 90% or more, 92% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% identical to an amino acid sequence set forth in any of SEQ ID NOs: 1-18.
- Subject nucleic acids may include sequences that encode (i) one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, or 6 or more) CDR sequences (e.g., those set forth in SEQ ID NOs: 2-4 and 6-8); (ii) a complete variable region (e.g., those set forth in SEQ ID NOs: 1 and 5); (iii) single-chain variable fragments (e.g., those set forth in SEQ ID NOs: 9-10); (iv) chimeric antibody sequences (e.g., those set forth in SEQ ID NOs: 1 1 -12); and/or (v) bispecific antibody sequences (e.g., those set forth in SEQ ID NOs: 13-18).
- a variable region sequence may be fused to any appropriate constant region sequence.
- the nucleic acid encoding can be inserted into a replicable vector for further cloning (amplification of the DNA) or for expression.
- DNA encoding a subject antibody can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).
- Many vectors are available.
- the vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.
- a subject anti-SIRPa antibody of this disclosure may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous or homologous polypeptide, which include a signal sequence or other polypeptide having a specific cleavage site at the N- terminus of the mature protein or polypeptide, an immunoglobulin constant region sequence, and the like.
- a heterologous signal sequence selected preferably may be one that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and process the native antibody signal sequence, the signal sequence is substituted by a prokaryotic signal sequence selected.
- An "isolated" nucleic acid molecule is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the antibody nucleic acid.
- An isolated nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated nucleic acid molecules therefore are distinguished from the nucleic acid molecule as it exists in natural cells.
- an isolated nucleic acid molecule includes a nucleic acid molecule contained in cells that ordinarily express the antibody where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.
- suitable host cells for cloning or expressing subject nucleic acids include, but are not necessary limited to prokaryote, yeast, or higher eukaryote cells.
- useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651 ); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR(CHO, Urlaub et al., Proc. Natl. Acad. Sci.
- mice Sertoli cells TM4, Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL- 1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51 ); TR1 cells (Mather et al., Annals N.Y. Acad. Sci.
- Host cells are transformed with the above-described expression or cloning vectors for anti-SIRPa antibody production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
- the antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique.
- affinity chromatography is the preferred purification technique.
- the suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody.
- Protein A can be used to purify antibodies that are based on human g1 , g2, or g4 heavy chains (Lindmark et al., J. Immunol. Meth. 62:1-13 (1983)). Protein G is usually recommended for human g3 (Guss et al., EMBO J. 5:15671575 (1986)).
- the matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose. Where the antibody comprises a CH 3 domain, the Bakerbond ABXTM resin (J. T. Baker, Phillipsburg, N.J.) is useful for purification.
- the mixture comprising the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5-4.5, preferably performed at low salt concentrations (e.g., from about 0-0.25M salt).
- the subject anti-SIRPa antibodies provided herein can be used in the modulation of phagocytosis (e.g. inducing phagocytosis).
- the subject anti-SIRPa antibodies provided herein can be used, in any method where the interaction between CD47 on one cell and SIRPa on another is to be blocked.
- Exemplary methods for using a subject anti-SIRPa antibody include, but are not limited to those methods described in U.S.
- antibody compositions may be administered to induce phagocytosis of cancer cells, inflammatory cells, and/or chronically infected cells that express CD47.
- a subject anti-SIRPa antibody provided herein may administered, alone or in combination with another antibody (e.g., in the form of a bispecific antibody) to a subject to treat symptoms, illnesses, and/or diseases.
- symptoms, illnesses, and/or diseases that can be treated with a subject anti-SIRPa antibody include, but are not limited to cancer (any form of cancer, including but not limited to: carcinomas, soft tissue tumors, sarcomas, teratomas, melanomas, leukemias, lymphomas, brain cancers, solid tumors, mesothelioma (MSTO), etc.); infection (e.g., chronic infection); and immunological diseases or disorders (e.g., an inflammatory disease)(e.g., multiple sclerosis, arthritis, and the like)(e.g., for immunosuppressive therapy).
- cancer any form of cancer, including but not limited to: carcinomas, soft tissue tumors, sarcomas, teratomas, melanomas, le
- a subject anti-SIRPa antibody can also be used for transplant conditioning (e.g., stem cell transplant, bone marrow transplant, etc.) (e.g., to destroy malignant cells, to provide immunosuppression to prevent the patient's body from rejecting the donor's cells/stem cells, etc.)
- transplant conditioning e.g., stem cell transplant, bone marrow transplant, etc.
- malignant cells e.g., to destroy malignant cells, to provide immunosuppression to prevent the patient's body from rejecting the donor's cells/stem cells, etc.
- cancer includes any form of cancer as described herein. Any cancer where the cancer cells express CD47 (e.g., in some cases, the cancer cells exhibit increased expression of CD47 compared to non-cancer cells), is a suitable cancer to be treated by the subject methods and compositions.
- subject anti-SIRPa antibodies can inhibit activation of an immune cell, and thus may inhibit cytokine and/or chemokine production of immune cells, particularly immune cells that express CD47 on the cell surface.
- an immune complex i.e., an antigen-antibody complex
- the presence of an immune complex (i.e., an antigen-antibody complex) interacting with an immune cell activates the immune cell and induces cytokine production by the immune cell, which can be inhibited by a subject anti-SIRPa antibody.
- Immune complexes can damage tissue by triggering Fc-receptor mediated inflammation, a process implicated in several human immunological diseases, for example, systemic lupus erythematosus, rheumatoid arthritis, and Sjoergen's syndrome.
- the subject anti-SIRPa antibodies described herein may be useful for altering immunoresponsiveness of an immune cell and thereby may be useful for treating or preventing an immunological disease or disorder.
- a subject anti-SIRPa antibody can be useful for treating or preventing, inhibiting, slowing the progression of, or reducing the symptoms associated with, an immunological disease or disorder.
- An immunological disorder includes an inflammatory disease or disorder and an autoimmune disease or disorder. While inflammation or an inflammatory response is a host's normal and protective response to an injury, inflammation can cause undesired damage.
- atherosclerosis is, at least in part, a pathological response to arterial injury and the consequent inflammatory cascade.
- a cardiovascular disease or disorder that may be treated which may include a disease or disorder that is also considered an immunological disease/disorder, includes for example, atherosclerosis, endocarditis, hypertension, or peripheral ischemic disease.
- a metabolic disease or disorder includes diabetes, obesity, and diseases and disorders associated with abnormal or altered mitochondrial function.
- An immunological disease or disorder may be an autoimmune disease or an inflammatory disease.
- the immunological disease or disorder is multiple sclerosis, rheumatoid arthritis, a spondyloarthropathy, systemic lupus erythematosus, graft versus host disease, an antibody-mediated inflammatory or autoimmune disease or disorder, sepsis, diabetes, psoriasis, atherosclerosis, Sjogren's syndrome, progressive systemic sclerosis, scleroderma, acute coronary syndrome, ischemic reperfusion, Crohn's Disease, endometriosis, glomerulonephritis, myasthenia gravis, idiopathic pulmonary fibrosis, asthma, acute respiratory distress syndrome (ARDS), vasculitis, or inflammatory autoimmune myositis.
- ARDS acute respiratory distress syndrome
- a spondyloarthropathy includes, for example, ankylosing spondylitis, reactive arthritis, enteropathic arthritis associated with inflammatory bowel disease, psoriatic arthritis, isolated acute anterior uveitis, undifferentiated spondyloarthropathy, Behcet's syndrome, and juvenile idiopathic arthritis.
- the anti-SIRPa antibodies described herein may also be useful for treating a cardiovascular disease or disorder, such as atherosclerosis, endocarditis, hypertension, or peripheral ischemic disease.
- the inflammatory disease is multiple sclerosis or arthritis (e.g., rheumatoid arthritis).
- a subject antibody combination or bispecific antibody finds use for treating inflammatory disease.
- a subject antibody combination or bispecific antibody e.g., anti-SIRPa in combination with anti- CD19, CD20, CD22, CD 52, and the like
- a subject antibody combination or bispecific antibody e.g., anti-SIRPa in combination with anti- CD19, CD20, CD22, CD 52, and the like
- a subject anti-SIRPa antibody can be used to alter (enhance or suppress in a statistically significant or biologically significant manner) the immunoresponsiveness of an immune cell.
- a subject anti-SIRPa antibody described herein may alter or affect the immunoresponsiveness of an immune cell by effecting a biological function or action, including any one or more (or at least one of) the following: inhibiting maturation of dendritic cells; impairing development of naive T cells into Th1 effector cells; suppressing cytokine release by dendritic cells; altering cell migration; inhibiting production of at least one cytokine, for example, at least one of TNF-. alpha., IL-12, IL-23, IFN-.
- GM-CSF gamma., GM-CSF, and IL- 6
- inhibiting immune complex-induced production of at least one cytokine by an immune cell such, for example, a dendritic cell
- inhibiting Fc-mediated cytokine production inhibiting Fc-mediated cytokine production
- suppressing a proinflammatory response a proinflammatory response.
- an immune response includes (1 ) a humoral response, in which antibodies specific for antigens are produced by differentiated B lymphocytes known as plasma cells, and (2) a cell mediated response, in which various types of T lymphocytes act to eliminate antigens by a number of mechanisms.
- helper T cells that are capable of recognizing specific antigens may respond by releasing soluble mediators such as cytokines to recruit additional cells of the immune system to participate in an immune response.
- cytotoxic T cells that are also capable of specific antigen recognition may respond by binding to and destroying or damaging an antigen-bearing cell or particle.
- An immune response in a host or subject may be determined by any number of well- known immunological methods.
- Such assays include, but are not limited to, in vivo or in vitro determination of soluble antibodies, soluble mediators such as cytokines (e.g., IFN-.
- IL-2, IL-4, IL-10, IL-12, IL-6, IL-23, TNF-.alpha., and TGF-.beta. lymphokines, chemokines, hormones, growth factors, and the like, as well as other soluble small peptide, carbohydrate, nucleotide and/or lipid mediators; cellular activation state changes as determined by altered functional or structural properties of cells of the immune system, for example cell proliferation, altered motility, induction of specialized activities such as specific gene expression or cytolytic behavior; cell maturation, such as maturation of dendritic cells in response to a stimulus; alteration in relationship between a Th1 response and a Th2 response; cellular differentiation by cells of the immune system, including altered surface antigen expression profiles or the onset of apoptosis (programmed cell death).
- IL-2, IL-4, IL-10, IL-12, IL-6, IL-23, TNF-.alpha., and TGF-.beta. lymph
- cytokines may be determined according to any convenient method, including ELISA, ELISPOT, mass spectrometry, and flow cytometry (to measure intracellular cytokines).
- Immune cell proliferation and clonal expansion resulting from an antigen-specific elicitation or stimulation of an immune response may be determined by isolating lymphocytes, such as spleen cells or cells from lymph nodes, stimulating the cells with antigen, and measuring cytokine production, cell proliferation and/or cell viability, such as by incorporation of tritiated thymidine or non-radioactive assays, such as MTT assays and the like.
- Th1 cytokines such as IFN-. gamma., IL-12, IL-2, and TNF-.beta.
- Type 2 cytokines such as IL-4, IL-5, IL- 9, IL-10, and IL-13.
- a subject antibody combination or bispecific antibody finds use for treating an inflammatory disease.
- a subject antibody combination or bispecific antibody e.g., anti-SIRPa in combination with anti- CD19, CD20, CD22, CD 52, and the like
- a subject antibody combination or bispecific antibody e.g., anti-SIRPa in combination with anti- CD19, CD20, CD22, CD 52, and the like
- a subject anti-SIRPa antibody provided herein may be used in a method of vaccination against human pathogens and/or or human cancer.
- a patient's own SIRPa expressing phagocytic cells e.g., macrophages, e.g., autologous macrophages
- inflicted cells e.g., cancer cells, cells with an intracellular infection, etc.
- subject anti-SIRPa antibody e.g., phagocytosis
- the phagocytic cells could be transplanted back into the patient to present antigens (e.g., antigens from the cancer cells, antigens from the pathogen, and the like) to the host immune system, thereby generating an adaptive immune response.
- the subject anti-SIRPa antibodies provided herein may be used in vitro in immunoassays in which they can be utilized in liquid phase or bound to a solid phase carrier.
- the anti-SIRPa antibodies in these immunoassays can be detectably labeled in various ways.
- types of immunoassays which can utilize anti-SI RPa antibodies of the disclosure are flow cytometry, e.g. FACS, MACS, immunohistochemistry, competitive and non-competitive immunoassays in either a direct or indirect format; and the like.
- the anti-SIRPa antibodies of the disclosure can be bound to many different carriers and used to detect the presence of SIRPa expressing cells.
- carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses and magnetite.
- the nature of the carrier can be either soluble or insoluble for purposes of the disclosure. Those skilled in the art will know of other suitable carriers for binding anti-SIRPa antibodies, or will be able to ascertain such, using routine experimentation.
- a label may be covalently or non-covalently attached to an antibody of the disclosure or a fragment thereof, including fragments consisting or comprising of CDR sequences.
- Examples of the types of labels which can be used in the present disclosure include enzymes, radioisotopes, fluorescent compounds, colloidal metals, chemiluminescent compounds, and bio-luminescent compounds.
- a subject anti-SIRPa antibody e.g., a labeled anti-SIRPa antibody
- imaging e.g., for imaging cancer, for imaging inflammation, and the like.
- a subject anti-SIRPa antibody can be used in a method of detecting SIRPa expressing cells in an individual.
- a subject anti-SIRPa antibody can be used to target specific cells (e.g., SIRPa expressing phagocytic cells, e.g., macrophages)
- the subject anti- SI RPa antibodies can be used to detect the presence of such cells (e.g., SIRPa expressing phagocytic cells) in body regions of interest (e.g., in a tumor, in an inflamed region, in an infected region, etc.).
- the detection of SIRPa expressing phagocytic cells using a subject anti-SIRPa antibody e.g., by using a subject anti-SIRPa antibody for imaging
- a subject anti-SIRPa antibody can be used to detect tumor-associated macrophages, which correlate with poor prognosis in many types of cancer.
- a subject anti-SIRPa antibody can be used to detect inflammation- and/or infection-associated macrophages.
- a subject anti- SIRPa antibody is labeled with a radioisotope (i.e., the antibody is radiolabeled) and used in a method of imaging cancer, inflammation, and/or infection, for example, via positron emission tomography (PET), single-photon emission computed tomography (SPECT), and the like.
- PET positron emission tomography
- SPECT single-photon emission computed tomography
- the antibody or a fragment thereof is attached to a nanoparticle, e.g. for use in imaging.
- Useful nanoparticles are those known in the art, for example including without limitation, Raman-silica-gold-nanoparticle (R-Si-Au-NP).
- the R-Si-Au-NPs consist of a Raman organic molecule, with a narrow-band spectral signature, adsorbed onto a gold core. Because the Raman organic molecule can be changed, each nanoparticles can carry its own signature, thereby allowing multiple nanoparticles to be independently detected simultaneously by multiplexing.
- the entire nanoparticle is encapsulated in a silica shell to hold the Raman organic molecule on the gold nanocore.
- Optional polyethylene glycol (PEG)-ylation of R-Si-Au- NPs increases their bioavailability and provides functional "handles" for attaching targeting moieties (see Thakor et al (201 1 ) Sci Transl Med. 3(79):79ra33; Jokerst et al. (201 1 ) Small. 7(5):625-33; Gao et al. (201 1 ) Biomaterials. 32(8):2141-8; each herein specifically incorporated by reference).
- SIRPa may be detected by the anti-SIRPa antibodies of the disclosure when present in biological fluids and on tissues, in vivo or in vitro.
- Any sample containing a detectable amount of SIRPa can be used.
- a sample can be a liquid such as urine, saliva, cerebrospinal fluid, blood, serum and the like, or a solid or semi-solid such as tissues, feces, biopsies, and the like, or, alternatively, a solid tissue such as those commonly used in histological diagnosis.
- Another labeling technique which may result in greater sensitivity consists of coupling the antibodies to low molecular weight haptens. These haptens can then be specifically detected by means of a second reaction. For example, it is common to use haptens such as biotin, which reacts with avidin, or dinitrophenol, pyridoxal, or fluorescein, which can react with specific anti-hapten antibodies.
- a subject anti-SIRPa antibody (including, for example, a bispecific macrophage engaging antibody) is used in combination with another antibody to treat an individual.
- a subject anti-SIRPa antibody can be combined (coadministered) with monoclonal antibodies directed against one or more cancer markers (e.g., CD19, CD20, CD22, CD24, CD25, CD30, CD33, CD38, CD44, CD52, CD56, CD70, CD96, CD97, CD99, CD123, CD279 (PD-1 ), EGFR, HER2, CD1 17, C-Met, PTHR2, HAVCR2 (TIM3), and the like).
- cancer markers e.g., CD19, CD20, CD22, CD24, CD25, CD30, CD33, CD38, CD44, CD52, CD56, CD70, CD96, CD97, CD99, CD123, CD279 (PD-1 ), EGFR, HER2, CD1 17, C-Met, PTHR2, HAVCR2
- the combination compositions can be synergistic in enhancing phagocytosis of target cells as compared to the use of single antibodies.
- CD47-directed agents e.g., anti-CD47 antibodies
- mAbs monoclonal antibodies
- rituximab anti-CD20
- trastuzumab anti-HER2+ breast cancer.
- FcRs Fc receptors
- ITAMs Immunoreceptor Tyrosine-based Activation Motifs
- a subject anti-SIRPa antibody is co-administered with (i.e., administered in combination with) an antibody that specifically binds a second antigen, e.g., a marker of a CD47-expressing cell (e.g., a cancer cell marker, a marker of an infected cell, etc.).
- a second antigen e.g., a marker of a CD47-expressing cell (e.g., a cancer cell marker, a marker of an infected cell, etc.).
- the second antigen is an antigen selected from: CD19, CD20, CD22, CD24, CD25, CD30, CD33, CD38, CD44, CD52, CD56, CD70, CD96, CD97, CD99, CD123, CD279 (PD-1 ), EGFR, HER2, CD1 17, C-Met, PTHR2, and HAVCR2 (TI M3).
- a subject anti-SIRPa antibody is co-administered with (i.e., administered in combination with) one or more (e.g., 2 or more, 3 or more, etc.) antibodies that each specifically bind an antigen selected from: CD19, CD20, CD22, CD24, CD25, CD30, CD33, CD38, CD44, CD52, CD56, CD70, CD96, CD97, CD99, CD123, CD279 (PD-1 ), EGFR, HER2, CD1 17, C- Met, PTHR2, and HAVCR2 (TI M3).
- one or more antibodies that each specifically bind an antigen selected from: CD19, CD20, CD22, CD24, CD25, CD30, CD33, CD38, CD44, CD52, CD56, CD70, CD96, CD97, CD99, CD123, CD279 (PD-1 ), EGFR, HER2, CD1 17, C- Met, PTHR2, and HAVCR2 (TI M3).
- a subject anti-SIRPa antibody is co-administered with 1 or more antibodies selected from: CETUXIMAB (binds EGFR), PANITUMUMAB (binds EGFR), RITUXIMAB (binds CD20), TRASTUZUMAB (binds HER2), PERTUZUMAB (binds HER2), ALEMTUZUMAB (binds CD52), and BRENTUXIMAB (binds CD30) , GEMTUZUMAB (binds CD33), LORVOTUZUMAB (binds CD56), IPILIMUMAB (binds CTLA-4 (CD152)), NIVOLUMAB (binds PD-1 (CD279)).
- a subject anti-SIRPa antibody that is administered to an individual is a multispecific antibody (e.g., a bispecific antibody).
- the bispecific antibody specifically binds to SIRPa and a second antigen (e.g., a cancer cell marker).
- the second antigen is selected from: CD19, CD20, CD22, CD24, CD25, CD30, CD33, CD38, CD44, CD52, CD56, CD70, CD96, CD97, CD99, CD123, CD279 (PD-1 ), EGFR, HER2, CD1 17, C-Met, PTHR2, and HAVCR2 (TIM3).
- Therapeutic formulations comprising one or more antibodies of the disclosure are prepared for storage by mixing the antibody having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions.
- the antibody composition will be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
- the "therapeutically effective amount" of the antibody to be administered will be governed by such considerations, and is the minimum amount necessary to prevent the CD47 associated disease.
- the therapeutic dose may be at least 0.01 mg/kg body weight, at least 0.05 mg/kg body weight; at least 0.1 mg/kg body weight, at least 0.5 mg/kg body weight, at least 1 mg/kg body weight, at least 2.5 mg/kg body weight, at least 5 mg/kg body weight, and not more than 300 mg/kg body weight. It will be understood by one of skill in the art that such guidelines will be adjusted for the molecular weight of the active agent, e.g. in the use of antibody fragments, or in the use of antibody conjugates.
- the dosage may also be varied for localized administration, e.g. intranasal, inhalation, eic, or for systemic administration, e.g. i.m., i.p., i.v., and the like.
- the antibody need not be, but is optionally formulated with one or more agents that potentiate activity, or that otherwise increase the therapeutic effect. These are generally used in the same dosages and with administration routes as used hereinbefore or about from 1 to 99% of the heretofore employed dosages.
- Acceptable carriers, excipients, or stabilizers are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyidimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, hist
- the active ingredients may also be entrapped in microcapsule prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsule and poly-(methylmethacylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
- colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
- the anti-SIRPa antibody is administered by any suitable means, including parenteral, subcutaneous, intraperitoneal, intrapulmonary, and intranasal.
- Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
- the anti-SIRPa antibody is suitably administered by pulse infusion, particularly with declining doses of the antibody.
- the appropriate dosage of antibody will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the antibody is administered for preventive purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician.
- the antibody is suitably administered to the patient at one time or over a series of treatments.
- an article of manufacture containing materials useful for the treatment of the disorders described above comprises a container and a label.
- Suitable containers include, for example, bottles, vials, syringes, and test tubes.
- the containers may be formed from a variety of materials such as glass or plastic.
- the container holds a composition which is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
- An active agent in the composition can be the anti-SIRPa antibody.
- the label on, or associated with, the container can indicate that the composition is used for treating the condition of choice.
- the article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
- a pharmaceutically-acceptable buffer such as phosphate-buffered saline, Ringer's solution and dextrose solution.
- It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
- a subject anti-SIRPa antibody of the present disclosure can be provided in a kit, i.e., a packaged combination of reagents in predetermined amounts with instructions for administration and/or for performing an assay.
- a subject kit can include one or more additional antibodies that can be used in combination with an anti-SIRPa antibody.
- a subject kit includes one or more antibodies that each binds a second antigen (e.g., a cancer cell marker).
- the second antigen is an antigen selected from: CD19, CD20, CD22, CD24, CD25, CD30, CD33, CD38, CD44, CD52, CD56, CD70, CD96, CD97, CD99, CD123, CD279 (PD-1 ), EGFR, HER2, CD1 17, C-Met, PTHR2, and HAVCR2 (TIM3).
- a subject kit includes a subject SIRPa antibody and one or more antibodies selected from: CETUXIMAB (binds EGFR), PANITUMUMAB (binds EGFR), RITUXIMAB (binds CD20), TRASTUZUMAB (binds HER2), PERTUZUMAB (binds HER2), ALEMTUZUMAB (binds CD52), and BRENTUXIMAB (binds CD30), GEMTUZUMAB (binds CD33), LORVOTUZUMAB (binds CD56), IPILIMUMAB (binds CTLA-4 (CD152)), and NIVOLUMAB (binds PD-1 (CD279)).
- the kit can include substrates and cofactors required by the enzyme (e.g., a substrate precursor which provides the detectable chromophore or fluorophore).
- substrates and cofactors required by the enzyme e.g., a substrate precursor which provides the detectable chromophore or fluorophore.
- other additives may be included such as stabilizers, buffers (e.g., a block buffer or lysis buffer) and the like.
- the relative amounts of the various reagents may be varied widely to provide for concentrations in solution of the reagents which substantially optimize the sensitivity of the assay.
- the reagents may be provided as dry powders, usually lyophilized, including excipients which on dissolution will provide a reagent solution having the appropriate concentration.
- VH variable heavy chain
- CDR-H2 IDPEDGET (SEQ ID NO: 3)
- CDR-H3 ARWGAY (SEQ ID NO: 4)
- VU variable light chain
- CDR-L2 STS (SEQ ID NO: 7)
- CDR-L3 HQWSSYPRT (SEQ ID NO: 8)
- Bispecific Macrophage Enhacing (BiME) antibodies we first focused our efforts on obtaining a monoclonal anti-SI RPa antibody that blocks CD47 binding with high affinity.
- KWAR23 antibody was purified from hybridoma supernatant by protein G chromatography and titrated on THP-1 cells in the presence of 100 nM fluorescent CD47/streptavidin tetramers. As demonstrated in Figure 1 KWAR23 potently inhibited CD47 binding with an IC 50 of ⁇ 270 pM.
- variable regions of KWAR23 were sequenced.
- KWAR23 scFvs were constructed using site overlap extension (SOE) PCR in two orientations: with an N-terminal light chain (LH scFv, see SEQ ID NO: 10) and conversely, with an N- terminal heavy-chain (HL scFv, see SEQ ID NO: 9).
- Both scFv's contained a 15-amino acid (GGGGS) 3 (SEQ ID NO: 19) linker between the variable fragments.
- GGGGS 15-amino acid
- KWAR23 greatly increased both the potency (-10 fold lower EC 50 ) and efficacy (-50-100% higher E max ) of tumor cell phagocytosis induced by cetuximab, trastuzumab, or rituximab alone (Figure 2).
- KWAR23 also enhanced the efficacy of anti-EGFR isotype lgG1 (cetuximab) and isotype lgG2 (panitumumab) demonstrating that the results are not specific to anti-CD20 ( Figure 3B).
- KWAR23 can enhance the efficacy of all IgG isotypes.
- multispecific antibodies that can bind both SI RPa and a second antigen (e.g., a cancer marker such as CD19, CD20, CD22, CD24, CD25, CD30, CD33, CD38, CD44, CD52, CD56, CD70, CD96, CD97, CD99, CD123, CD279 (PD-1 ), EGFR, HER2, CD1 17, C-Met, PTHR2, HAVCR2 (TIM3), and the like).
- Figure 4A depicts a schematic of proposed activity of an exemplary subject bispecific antibody (also referred to as a Bispecific Macrophage Enhacing (BiME) antibody).
- a second antigen e.g., a cancer marker such as CD19, CD20, CD22, CD24, CD25, CD30, CD33, CD38, CD44, CD52, CD56, CD70, CD96, CD97, CD99, CD123, CD279 (PD-1 ), EGFR, HER2, CD1 17, C-Met, PTHR
- FIG 4B depicts a schematic of an exemplary anti-CD20 (and anti-SIRPa) BiME antibody.
- phagocytosis was assayed when Raji lymphoma cells were contacted with a subject bispecific antibody in the presence of phagocytic cells ( Figure 4C).
- the bispecific antibody tested was a dual-variable-domain immunoglobulin (DVD-lg) (with a heavy chain having the amino acid sequence set forth in SEQ ID NO: 13, and a light chain having the amino acid sequence set forth in SEQ ID NO: 14) that specifically binds SIRPa and CD20 (see Figure 4B).
- DVD-lg dual-variable-domain immunoglobulin
- FIG. 5A- 5B show binding of the CD20 BiME to yeast expressing hSIRPa, as detected by an anti-human lgG4 Fc antibody conjugated to Alexa fluor-647 and an anti-rituximab antibody conjugated to FITC. Binding of KWAR23 to yeast expressing hSIRPa was detected by the anti-human lgG4 Fc antibody but not the anti-rituximab antibody.
- Anti-SIRPa antibody enhances ADCP and ADCC of cancer-targeting antibodies as shown in Figures 6A-E.
- Anti-SIRPa antibody enhances antibody- dependent cellular phagocytosis (ADCP) of cancer-targeting antibodies by human macrophages: A. KWAR23 + rituximab (anti-CD20) for human lymphoma cancer cells (Raji); B. KWAR23 + trastuzumab (anti-Her2) for human breast cancer cells (SKBR3); C. KWAR23 + vorsetuzumab (anti-CD70) for human renal cell cancer (RCC10, TK10, Cakil ).
- Anti-SIRPa antibody enhances antibody-dependent cellular cytotoxicty (ADCC) of cancer- targeting antibodies by human neutrophils: D. KWAR23 + rituximab (anti-CD20) for human lymphoma cancer cells (Raji); E. KWAR23 + trastuzumab (anti-Her2) for human breast cancer cells (SKBR3).
- Bispecific macrophages enhancing antibodies enhance ADCP and ADCC compared to the parental cancer-targeting antibodies as shown in Figures 7A-7E.
- Anti-SIRPa antibody (KWAR23) BiMEs enhance antibody-dependent cellular phagocytosis (ADCP) of cancer-targeting antibodies by human macrophages: A. Anti-CD20 BiME (KWAR23 + rituximab (anti-CD20)) for human lymphoma cancer cells (Raji); B. Anti-Her2 BiME (KWAR23 + trastuzumab (anti-Her2)) for human breast cancer cells (SKBR3); C.
- Anti-CD70 BiME (KWAR23 + vorsetuzumab (anti-CD70)) for human renal cell cancer (RCC10, TK10, Cakil ).
- Anti-SIRPa antibody (KWAR23) BiMEs enhance antibody-dependent cellular cytotoxicty (ADCC) of cancer-targeting antibodies by human neutrophils: D. Anti-CD20 BiME (KWAR23 + rituximab (anti-CD20)) for human lymphoma cancer cells (Raji); E. Anti-Her2 BiME (KWAR23 + trastuzumab (anti-Her2)) for human breast cancer cells (SKBR3).
- KWAR23 enhances phagocytosis in response to cetuximab in the presence of downstream mutations in the EGFR signaling pathway, shown in Figure 8.
- KWAR23 enhances phagocytosis in response to glycoengineered antibodies as shown in Figure 9.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/122,560 US10081680B2 (en) | 2014-03-11 | 2015-03-11 | Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies |
EP15762121.0A EP3116544A4 (en) | 2014-03-11 | 2015-03-11 | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
SG11201607143UA SG11201607143UA (en) | 2014-03-11 | 2015-03-11 | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
CN201580013178.2A CN106456749B (en) | 2014-03-11 | 2015-03-11 | Anti-sirpa antibodies and bispecific macrophage-enhancing antibodies |
AU2015229448A AU2015229448B2 (en) | 2014-03-11 | 2015-03-11 | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
JP2016551302A JP6606505B2 (en) | 2014-03-11 | 2015-03-11 | Anti-SIRPα antibody and bispecific macrophage enhancing antibody |
CA2939293A CA2939293C (en) | 2014-03-11 | 2015-03-11 | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
US16/030,377 US10781256B2 (en) | 2014-03-11 | 2018-07-09 | Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461951226P | 2014-03-11 | 2014-03-11 | |
US61/951,226 | 2014-03-11 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/122,560 A-371-Of-International US10081680B2 (en) | 2014-03-11 | 2015-03-11 | Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies |
US16/030,377 Continuation US10781256B2 (en) | 2014-03-11 | 2018-07-09 | Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015138600A2 true WO2015138600A2 (en) | 2015-09-17 |
WO2015138600A3 WO2015138600A3 (en) | 2015-11-26 |
Family
ID=54072584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/019954 WO2015138600A2 (en) | 2014-03-11 | 2015-03-11 | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
Country Status (8)
Country | Link |
---|---|
US (2) | US10081680B2 (en) |
EP (1) | EP3116544A4 (en) |
JP (1) | JP6606505B2 (en) |
CN (1) | CN106456749B (en) |
AU (1) | AU2015229448B2 (en) |
CA (1) | CA2939293C (en) |
SG (1) | SG11201607143UA (en) |
WO (1) | WO2015138600A2 (en) |
Cited By (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017068164A1 (en) | 2015-10-21 | 2017-04-27 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
WO2017100462A2 (en) | 2015-12-11 | 2017-06-15 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with dual targeting of cd47 and egfr |
CN107149682A (en) * | 2016-03-04 | 2017-09-12 | 复旦大学 | A kind of targeting CD47 immunologic test point inhibitor medicaments composition and preparation method thereof |
WO2017220988A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Multispecific antibodies for immuno-oncology |
WO2018008470A1 (en) * | 2016-07-05 | 2018-01-11 | 国立大学法人神戸大学 | Antitumor agent |
WO2018014067A1 (en) * | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd47 combination therapy |
WO2018026600A1 (en) | 2016-08-03 | 2018-02-08 | The Board Of Trustees Of The Leland Stanford Junior University | Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy |
WO2018057669A1 (en) | 2016-09-21 | 2018-03-29 | Alexo Therapeutics Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
US9957576B2 (en) | 2016-04-21 | 2018-05-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
WO2017178653A3 (en) * | 2016-04-14 | 2018-07-05 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
WO2018141964A1 (en) * | 2017-02-06 | 2018-08-09 | Orionis Biosciences Nv | Targeted chimeric proteins and uses thereof |
WO2018149938A1 (en) | 2017-02-17 | 2018-08-23 | Ose Immunotherapeutics | New uses of anti-sirpg antibodies |
NL2018708B1 (en) * | 2017-04-13 | 2018-10-24 | Aduro Biotech Holdings Europe B V | ANTI-SIRPα ANTIBODIES |
WO2018200766A1 (en) | 2017-04-26 | 2018-11-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
WO2018198076A1 (en) | 2017-04-28 | 2018-11-01 | Aduro Biotech, Inc. | Bis 2'-5'-rr-(3'f-a)(3'f-a) cyclic dinucleotide compound and uses thereof |
WO2018210793A2 (en) | 2017-05-16 | 2018-11-22 | Synthon Biopharmaceuticals B.V. | ANTI-SIRPα ANTIBODIES |
KR20180134397A (en) * | 2016-04-14 | 2018-12-18 | 오제 이뮈노테라프틱스 | Novel anti-SIRPa antibodies and their therapeutic applications |
WO2019023347A1 (en) | 2017-07-26 | 2019-01-31 | Forty Seven, Inc. | Anti-sirp-alpha antibodies and related methods |
WO2019022600A1 (en) * | 2017-07-24 | 2019-01-31 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction |
JP2019503713A (en) * | 2015-12-28 | 2019-02-14 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | Variable region of NKp46 binding protein |
CN109414490A (en) * | 2016-07-01 | 2019-03-01 | 小利兰·斯坦福大学理事会 | Inhibition immunity receptor suppressing method and composition |
WO2019073080A1 (en) * | 2017-10-13 | 2019-04-18 | Ose Immunotherapeutics | Modified anti-sirpa antibodies and uses thereof |
WO2019141732A1 (en) * | 2018-01-16 | 2019-07-25 | Argenx Bvba | Cd70 combination therapy |
WO2019175218A1 (en) | 2018-03-13 | 2019-09-19 | Ose Immunotherapeutics | Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies |
EP3186395B1 (en) | 2014-08-26 | 2019-09-25 | The Board of Trustees of the Leland Stanford Junior University | Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling |
CN110325549A (en) * | 2016-12-09 | 2019-10-11 | 艾利妥 | Anti- SIRP Alpha antibodies and its application method |
WO2018190719A3 (en) * | 2017-04-13 | 2019-10-31 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
WO2019226973A1 (en) | 2018-05-25 | 2019-11-28 | Alector Llc | Anti-sirpa antibodies and methods of use thereof |
WO2020091596A1 (en) | 2018-10-29 | 2020-05-07 | Umc Utrecht Holding B.V. | Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils |
WO2020099653A1 (en) | 2018-11-15 | 2020-05-22 | Byondis B.V. | HUMANIZED ANTI-SIRPα ANTIBODIES |
WO2020112870A1 (en) | 2018-11-28 | 2020-06-04 | Forty Seven, Inc. | Genetically modified hspcs resistant to ablation regime |
EP3209691B1 (en) | 2014-10-24 | 2020-07-15 | OSE Immunotherapeutics | Compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
US10927173B2 (en) | 2016-01-11 | 2021-02-23 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-CD47 monoclonal antibodies |
WO2021076908A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
WO2021087064A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
US11059909B2 (en) | 2019-03-27 | 2021-07-13 | Umc Utrecht Holding B.V. | Engineered IgA antibodies and methods of use |
US20210220401A1 (en) * | 2015-12-01 | 2021-07-22 | The Trustees Of The University Of Pennsylvania | Compositions and Methods for Selective Phagocytosis of Human Cancer Cells |
US11072665B2 (en) | 2011-03-16 | 2021-07-27 | Argenx Bvba | Antibodies to CD70 |
US11078272B2 (en) | 2017-03-09 | 2021-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of CD47 pathway |
WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
CN114040925A (en) * | 2019-12-24 | 2022-02-11 | 礼新医药科技(上海)有限公司 | anti-SIRP alpha monoclonal antibody and application thereof |
US11292850B2 (en) | 2018-03-21 | 2022-04-05 | ALX Oncology Inc. | Antibodies against signal-regulatory protein α and methods of use |
US11401329B2 (en) | 2017-08-02 | 2022-08-02 | Phanes Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
WO2022219076A1 (en) | 2021-04-14 | 2022-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to improve the anti-tumoral activity of macrophages |
WO2022221304A1 (en) | 2021-04-14 | 2022-10-20 | Gilead Sciences, Inc. | CO-INHIBITION OF CD47/SIRPα BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
WO2022254379A1 (en) | 2021-06-04 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Anti-sirp-alpha antibodies |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023278377A1 (en) | 2021-06-29 | 2023-01-05 | Seagen Inc. | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
US11555073B2 (en) | 2018-12-20 | 2023-01-17 | 23Andme, Inc. | Anti-CD96 antibodies and methods of use thereof |
US11571475B1 (en) | 2014-08-22 | 2023-02-07 | University Of Bern | Anti-CD70 and BCR-ABL inhibitor combination therapy |
WO2023020459A1 (en) | 2021-08-17 | 2023-02-23 | 杭州九源基因工程有限公司 | MONOCLONAL ANTIBODY TARGETING SIRPα AND USE THEREOF |
US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
US20230139592A1 (en) * | 2016-12-22 | 2023-05-04 | Wake Forest University Health Sciences | Sirp-gamma targeted agents for use in the treatment of cancer |
WO2023094698A1 (en) | 2021-11-29 | 2023-06-01 | Ose Immunotherapeutics | Specific antagonist anti-sirpg antibodies |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US11712468B2 (en) | 2018-12-18 | 2023-08-01 | argenx BV | CD70 combination therapy |
WO2023147418A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | Parp7 inhibitors |
WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
WO2023196784A1 (en) | 2022-04-05 | 2023-10-12 | Gilead Sciences, Inc. | Combinations of antibody therapies for treating colorectal cancer |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
US11802153B2 (en) | 2017-10-18 | 2023-10-31 | Forty Seven, Inc. | Anti-CD47 agent-based ovarian cancer therapy |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
US11891450B2 (en) | 2018-02-12 | 2024-02-06 | Forty Seven, Inc. | Anti-CD47 agent-based treatment of CD20-positive cancer |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
US12060422B2 (en) | 2018-06-29 | 2024-08-13 | Alector Llc | Anti-SIRP-Beta1 antibodies and methods of use thereof |
KR102702926B1 (en) | 2017-04-13 | 2024-09-06 | 사이로파 비.브이. | Anti-SIRP alpha antibody |
US12084497B2 (en) | 2018-08-08 | 2024-09-10 | Orionis Biosciences, Inc. | SIRP1α targeted chimeric proteins and uses thereof |
US12084499B2 (en) | 2018-09-27 | 2024-09-10 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2965198C (en) | 2008-01-15 | 2021-02-16 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
US11072655B2 (en) * | 2008-01-15 | 2021-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
US10550187B2 (en) * | 2014-10-24 | 2020-02-04 | Incept, Llc | Extra luminal scaffold |
US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
WO2017058859A1 (en) | 2015-09-29 | 2017-04-06 | Celgene Corporation | Pd-1 binding proteins and methods of use thereof |
US10751414B2 (en) | 2016-09-19 | 2020-08-25 | Celgene Corporation | Methods of treating psoriasis using PD-1 binding antibodies |
JP2019534859A (en) | 2016-09-19 | 2019-12-05 | セルジーン コーポレイション | Method for treating vitiligo using PD-1 binding protein |
CN108588126B (en) | 2017-03-31 | 2020-04-10 | 北京百奥赛图基因生物技术有限公司 | Preparation method and application of humanized modified animal model of CD47 gene |
EP3700540A4 (en) | 2017-10-24 | 2021-11-10 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+ cells |
WO2019084067A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | Anti-cd117 antibodies and methods of using same |
MX2020004140A (en) | 2017-10-24 | 2020-08-13 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd117+ cells. |
WO2019109357A1 (en) * | 2017-12-08 | 2019-06-13 | 杭州翰思生物医药有限公司 | Anti-pd-1/cd47 bispecific antibody and application thereof |
MX2020013068A (en) * | 2018-07-10 | 2021-03-02 | Univ Kobe Nat Univ Corp | Anti-sirpî± antibody. |
CN109535258A (en) * | 2018-10-26 | 2019-03-29 | 上海科弈药业科技有限公司 | It is a kind of for the multi-functional fusion protein of Her2+ tumour and its application |
EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
US20220105166A1 (en) * | 2019-01-25 | 2022-04-07 | Sqz Biotechnologies Company | Anucleate cell-derived vaccines |
JOP20210233A1 (en) | 2019-02-26 | 2023-01-30 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
WO2020198353A1 (en) * | 2019-03-26 | 2020-10-01 | Forty Seven, Inc. | Multispecific agents for treatment of cancer |
US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
JOP20210304A1 (en) | 2019-05-14 | 2023-01-30 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
US20210347908A1 (en) * | 2019-08-20 | 2021-11-11 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-sirpa antibodies |
MX2022002613A (en) | 2019-09-03 | 2022-06-02 | Myeloid Therapeutics Inc | Methods and compositions for genomic integration. |
US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
EP4185387A4 (en) * | 2020-07-24 | 2024-08-21 | Univ Leland Stanford Junior | Compositions and methods for modulation of sirpalpha-mediated signaling |
AU2021376354A1 (en) | 2020-11-04 | 2023-06-22 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
CN112574310B (en) * | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | anti-SIRP alpha antibodies and uses thereof |
WO2022197949A2 (en) | 2021-03-17 | 2022-09-22 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
WO2023202672A1 (en) * | 2022-04-20 | 2023-10-26 | Biosion Inc. | Antibodies targeting sirp-alpha and uses thereof |
WO2024153193A1 (en) * | 2023-01-18 | 2024-07-25 | Elpiscience (Suzhou) Biopharma, Ltd. | Bi-specific molecules targeting sirpa and claudin 18.2 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6663863B2 (en) * | 2000-03-17 | 2003-12-16 | Millennium Pharmaceuticals, Inc. | Method of inhibiting stenosis and restenosis |
US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
US7297336B2 (en) * | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
WO2005036180A1 (en) * | 2003-10-08 | 2005-04-21 | The Government Of The United States Of America As Represented By The Secretary Of Department Of Health And Human Services | Analysis methods using biomarkers concentrated with biomarkers attractant molecules |
WO2008143679A2 (en) * | 2006-06-01 | 2008-11-27 | Verenium Corporation | Nucleic acids and proteins and methods for making and using them |
US20110229415A1 (en) * | 2007-08-06 | 2011-09-22 | Sylvia Daunert | Semi-synthetic antibodies as recognition elements |
WO2009046541A1 (en) | 2007-10-11 | 2009-04-16 | University Health Network | MODULATION OF SIRPα - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR |
CA2965198C (en) | 2008-01-15 | 2021-02-16 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
CA3054220C (en) | 2008-01-15 | 2022-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for manilpulating phagocytosis mediated by cd47 |
EP2111869A1 (en) * | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
AU2010220421B9 (en) * | 2009-03-02 | 2015-03-05 | Aduro Biotech Holdings, Europe B.V. | Antibodies against a proliferating inducing ligand (APRIL) |
SI2477648T1 (en) | 2009-09-15 | 2022-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
CN101880324B (en) * | 2010-05-25 | 2012-10-17 | 中国人民解放军第二军医大学 | Monoclonal antibody of anti-human SIRPalpha, cell strain, preparation method and application thereof |
US9334515B2 (en) * | 2010-07-30 | 2016-05-10 | The Regents Of The University Of California | Polypeptides for use in the deconstruction of cellulose |
US8841418B2 (en) * | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
WO2013056352A1 (en) | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
-
2015
- 2015-03-11 EP EP15762121.0A patent/EP3116544A4/en not_active Ceased
- 2015-03-11 WO PCT/US2015/019954 patent/WO2015138600A2/en active Application Filing
- 2015-03-11 AU AU2015229448A patent/AU2015229448B2/en active Active
- 2015-03-11 CA CA2939293A patent/CA2939293C/en active Active
- 2015-03-11 JP JP2016551302A patent/JP6606505B2/en active Active
- 2015-03-11 CN CN201580013178.2A patent/CN106456749B/en active Active
- 2015-03-11 US US15/122,560 patent/US10081680B2/en active Active
- 2015-03-11 SG SG11201607143UA patent/SG11201607143UA/en unknown
-
2018
- 2018-07-09 US US16/030,377 patent/US10781256B2/en active Active
Cited By (192)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11072665B2 (en) | 2011-03-16 | 2021-07-27 | Argenx Bvba | Antibodies to CD70 |
US11434298B2 (en) | 2011-03-16 | 2022-09-06 | argenx BV | Antibodies to CD70 |
US11571475B1 (en) | 2014-08-22 | 2023-02-07 | University Of Bern | Anti-CD70 and BCR-ABL inhibitor combination therapy |
EP3656869B1 (en) | 2014-08-26 | 2020-11-11 | The Board of Trustees of the Leland Stanford Junior University | Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling |
US11419897B2 (en) | 2014-08-26 | 2022-08-23 | The Board Of Trustees Of The Leland Stanford Junior University | Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling |
EP3186395B1 (en) | 2014-08-26 | 2019-09-25 | The Board of Trustees of the Leland Stanford Junior University | Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling |
EP4257145A3 (en) * | 2014-08-26 | 2023-10-18 | The Board of Trustees of the Leland Stanford Junior University | Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling |
EP3209691B1 (en) | 2014-10-24 | 2020-07-15 | OSE Immunotherapeutics | Compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
WO2017068164A1 (en) | 2015-10-21 | 2017-04-27 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
EP4186927A1 (en) | 2015-10-21 | 2023-05-31 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
US20210220401A1 (en) * | 2015-12-01 | 2021-07-22 | The Trustees Of The University Of Pennsylvania | Compositions and Methods for Selective Phagocytosis of Human Cancer Cells |
US12037402B2 (en) | 2015-12-11 | 2024-07-16 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with dual targeting of CD47 and EGFR |
CN108367073A (en) * | 2015-12-11 | 2018-08-03 | 小利兰·斯坦福大学托管委员会 | Carry out treating cancer with dual-target CD47 and EGFR |
AU2020202712B2 (en) * | 2015-12-11 | 2023-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with dual targeting of CD47 and EGFR |
WO2017100462A2 (en) | 2015-12-11 | 2017-06-15 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with dual targeting of cd47 and egfr |
JP7494245B2 (en) | 2015-12-11 | 2024-06-03 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Dual targeting of CD47 and EGFR for cancer therapy |
JP2019505485A (en) * | 2015-12-11 | 2019-02-28 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Cancer treatment by dual targeting of CD47 and EGFR |
EP3386545A4 (en) * | 2015-12-11 | 2019-06-05 | The Board of Trustees of the Leland Stanford Junior University | Treatment of cancer with dual targeting of cd47 and egfr |
US11130813B2 (en) | 2015-12-11 | 2021-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with dual targeting of CD47 and EGFR |
JP7077226B2 (en) | 2015-12-11 | 2022-05-30 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Cancer treatment with double targeting of CD47 and EGFR |
JP2022116095A (en) * | 2015-12-11 | 2022-08-09 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Treatment of cancer with dual targeting of cd47 and egfr |
JP2022137054A (en) * | 2015-12-28 | 2022-09-21 | イナート・ファルマ・ソシエテ・アノニム | VARIABLE REGION OF NKp46-BOUND PROTEIN |
JP7091250B2 (en) | 2015-12-28 | 2022-06-27 | イナート・ファルマ・ソシエテ・アノニム | Variable region of NKp46 binding protein |
JP2019503713A (en) * | 2015-12-28 | 2019-02-14 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | Variable region of NKp46 binding protein |
JP7551693B2 (en) | 2015-12-28 | 2024-09-17 | イナート・ファルマ・ソシエテ・アノニム | Variable region of NKp46 binding protein |
US11643461B2 (en) | 2016-01-11 | 2023-05-09 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-CD47 monoclonal antibodies |
US10927173B2 (en) | 2016-01-11 | 2021-02-23 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-CD47 monoclonal antibodies |
US12060423B2 (en) | 2016-01-11 | 2024-08-13 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-CD47 monoclonal antibodies |
CN107149682A (en) * | 2016-03-04 | 2017-09-12 | 复旦大学 | A kind of targeting CD47 immunologic test point inhibitor medicaments composition and preparation method thereof |
CN109071664A (en) * | 2016-04-14 | 2018-12-21 | Ose免疫疗法 | Novel anti-SIRPa antibody and its treatment use |
JP7549626B2 (en) | 2016-04-14 | 2024-09-11 | オーエスイー イムノセラピューティクス | Novel anti-SIRPa antibodies and their therapeutic applications |
CN109071664B (en) * | 2016-04-14 | 2023-02-21 | Ose免疫疗法 | Novel anti-SIRPa antibodies and therapeutic uses thereof |
JP2019520034A (en) * | 2016-04-14 | 2019-07-18 | オーエスイー イムノセラピューティクス | Novel anti-SIRPa antibodies and their therapeutic applications |
WO2017178653A3 (en) * | 2016-04-14 | 2018-07-05 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
JP2022169504A (en) * | 2016-04-14 | 2022-11-09 | オーエスイー イムノセラピューティクス | Novel anti-SIRPa antibodies and their therapeutic applications |
JP7491666B2 (en) | 2016-04-14 | 2024-05-28 | オーエスイー イムノセラピューティクス | Novel anti-SIRPa antibodies and their therapeutic applications |
IL262251B2 (en) * | 2016-04-14 | 2023-09-01 | Ose Immunotherapeutics | New anti-sirpa antibodies and their therapeutic applications |
KR102355240B1 (en) * | 2016-04-14 | 2022-01-25 | 오제 이뮈노테라프틱스 | Novel anti-SIRPa antibodies and methods of their therapeutic application |
US11279766B2 (en) | 2016-04-14 | 2022-03-22 | Ose Immunotherapeutics | Anti-SIRPa antibodies and their therapeutic applications |
IL262251B1 (en) * | 2016-04-14 | 2023-05-01 | Ose Immunotherapeutics | New anti-sirpa antibodies and their therapeutic applications |
KR20180134397A (en) * | 2016-04-14 | 2018-12-18 | 오제 이뮈노테라프틱스 | Novel anti-SIRPa antibodies and their therapeutic applications |
US9957576B2 (en) | 2016-04-21 | 2018-05-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
WO2017220990A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
WO2017220988A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Multispecific antibodies for immuno-oncology |
EP3478315A4 (en) * | 2016-07-01 | 2020-03-25 | The Board of Trustees of the Leland Stanford Junior University | Inhibitory immune receptor inhibition methods and compositions |
JP2019527204A (en) * | 2016-07-01 | 2019-09-26 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Suppressive immunoreceptor inhibition method and composition |
CN109414490A (en) * | 2016-07-01 | 2019-03-01 | 小利兰·斯坦福大学理事会 | Inhibition immunity receptor suppressing method and composition |
US20220106394A1 (en) * | 2016-07-05 | 2022-04-07 | National University Corporation Kobe University | Antitumor Agent |
WO2018008470A1 (en) * | 2016-07-05 | 2018-01-11 | 国立大学法人神戸大学 | Antitumor agent |
JPWO2018008470A1 (en) * | 2016-07-05 | 2019-04-18 | 国立大学法人神戸大学 | Antitumor agent |
US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
US11618784B2 (en) | 2016-07-19 | 2023-04-04 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD47 combination therapy |
WO2018014067A1 (en) * | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd47 combination therapy |
EP3493845A4 (en) * | 2016-08-03 | 2020-04-15 | The Board of Trustees of the Leland Stanford Junior University | Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy |
JP7369620B2 (en) | 2016-08-03 | 2023-10-26 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Enhancement of efficacy of anti-SlRPα antibody therapy by disruption of Fc receptor binding on macrophages |
CN109862910A (en) * | 2016-08-03 | 2019-06-07 | 小利兰·斯坦福大学托管委员会 | The effect of Fc receptor engagement destroyed on macrophage enhances anti-SIRP Alpha antibodies therapy |
WO2018026600A1 (en) | 2016-08-03 | 2018-02-08 | The Board Of Trustees Of The Leland Stanford Junior University | Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy |
US20200262918A1 (en) * | 2016-08-03 | 2020-08-20 | The Board Of Trustees Of The Leland Stanford Junior University | Disrupting FC Receptor Engagement on Macrophages Enhances Efficacy of Anti-SIRPalpha Antibody Therapy |
JP2022065039A (en) * | 2016-08-03 | 2022-04-26 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | DISRUPTING Fc RECEPTOR ENGAGEMENT ON MACROPHAGES ENHANCES EFFICACY OF ANTI-SIRPα ANTIBODY THERAPY |
JP2019534845A (en) * | 2016-08-03 | 2019-12-05 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Enhanced efficacy of anti-SlRPα antibody therapy by disrupting Fc receptor binding on macrophages |
US10611842B2 (en) | 2016-08-03 | 2020-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPα antibody therapy |
US11718675B2 (en) | 2016-08-03 | 2023-08-08 | The Board Of Trustees Of The Leland Stanford Junior University | Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy |
JP2022003031A (en) * | 2016-09-21 | 2022-01-11 | エーエルエックス オンコロジー インコーポレイテッド | ANTIBODIES AGAINST SIGNAL-REGULATORY PROTEIN α AND METHODS OF USE |
US11242404B2 (en) | 2016-09-21 | 2022-02-08 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
JP7508425B2 (en) | 2016-09-21 | 2024-07-01 | エーエルエックス オンコロジー インコーポレイテッド | Antibodies to signal regulatory protein alpha and methods of use |
IL265439B2 (en) * | 2016-09-21 | 2024-08-01 | Alx Oncology Inc | Antibodies against signal-regulatory protein alpha and methods of use |
IL265439B1 (en) * | 2016-09-21 | 2024-04-01 | Alx Oncology Inc | Antibodies against signal-regulatory protein alpha and methods of use |
EP3515490A4 (en) * | 2016-09-21 | 2020-04-29 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
US11401338B2 (en) | 2016-09-21 | 2022-08-02 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
EP4119580A1 (en) | 2016-09-21 | 2023-01-18 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
WO2018057669A1 (en) | 2016-09-21 | 2018-03-29 | Alexo Therapeutics Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
CN110325549B (en) * | 2016-12-09 | 2024-03-08 | 艾利妥 | anti-SIRP alpha antibodies and methods of use thereof |
CN110325549A (en) * | 2016-12-09 | 2019-10-11 | 艾利妥 | Anti- SIRP Alpha antibodies and its application method |
JP2020500540A (en) * | 2016-12-09 | 2020-01-16 | アレクトル エルエルシー | Anti-SIRP-α antibody and method of using the same |
JP2023022036A (en) * | 2016-12-09 | 2023-02-14 | アレクトル エルエルシー | ANTI-SIRP-α ANTIBODIES AND METHODS OF USE THEREOF |
US11779642B2 (en) | 2016-12-09 | 2023-10-10 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
JP7173971B2 (en) | 2016-12-09 | 2022-11-16 | アレクトル エルエルシー | ANTI-SIRP-α ANTIBODY AND METHOD OF USE THEREOF |
US20230139592A1 (en) * | 2016-12-22 | 2023-05-04 | Wake Forest University Health Sciences | Sirp-gamma targeted agents for use in the treatment of cancer |
KR20190115005A (en) * | 2017-02-06 | 2019-10-10 | 오리오니스 바이오사이언시스 엔브이 | Targeted Chimeric Proteins and Uses thereof |
WO2018141964A1 (en) * | 2017-02-06 | 2018-08-09 | Orionis Biosciences Nv | Targeted chimeric proteins and uses thereof |
IL268346B1 (en) * | 2017-02-06 | 2024-04-01 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
JP2020506727A (en) * | 2017-02-06 | 2020-03-05 | オリオンズ バイオサイエンス エヌブイ | Targeted chimeric proteins and uses thereof |
IL268346B2 (en) * | 2017-02-06 | 2024-08-01 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
JP7476467B2 (en) | 2017-02-06 | 2024-05-01 | オリオンズ バイオサイエンス ビーブイ | Targeted chimeric proteins and uses thereof |
US11384154B2 (en) | 2017-02-06 | 2022-07-12 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
KR102642385B1 (en) * | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | Targeted chimeric proteins and uses thereof |
AU2018216032B2 (en) * | 2017-02-06 | 2022-04-07 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
CN110546160A (en) * | 2017-02-06 | 2019-12-06 | 奥里尼斯生物科学公司 | Targeted chimeric proteins and uses thereof |
WO2018149938A1 (en) | 2017-02-17 | 2018-08-23 | Ose Immunotherapeutics | New uses of anti-sirpg antibodies |
CN110300764A (en) * | 2017-02-17 | 2019-10-01 | Ose免疫疗法 | The new application of anti-SIRPg antibody |
US11078272B2 (en) | 2017-03-09 | 2021-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of CD47 pathway |
WO2018190719A3 (en) * | 2017-04-13 | 2019-10-31 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
TWI841526B (en) * | 2017-04-13 | 2024-05-11 | 荷蘭商賽羅帕公司 | ANTI-SIRPα ANTIBODIES |
NL2018708B1 (en) * | 2017-04-13 | 2018-10-24 | Aduro Biotech Holdings Europe B V | ANTI-SIRPα ANTIBODIES |
JP2020516300A (en) * | 2017-04-13 | 2020-06-11 | アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. | Anti-SIRP alpha antibody |
KR102702926B1 (en) | 2017-04-13 | 2024-09-06 | 사이로파 비.브이. | Anti-SIRP alpha antibody |
US10851164B2 (en) | 2017-04-13 | 2020-12-01 | Aduro Biotech Holdings, Europe B.V. | Anti-SIRPα antibodies |
JP7160833B2 (en) | 2017-04-13 | 2022-10-25 | サイロパ ビー.ブイ. | anti-SIRP alpha antibody |
EP3615074A4 (en) * | 2017-04-26 | 2020-05-13 | Mayo Foundation for Medical Education and Research | Methods and materials for treating cancer |
US11555056B2 (en) | 2017-04-26 | 2023-01-17 | Mayo Foundation for Medical Education and Research and Board of Regents | Methods and materials for treating cancer |
WO2018200766A1 (en) | 2017-04-26 | 2018-11-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
US10975114B2 (en) | 2017-04-28 | 2021-04-13 | Chinook Therapeutics, Inc. | Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof |
WO2018198076A1 (en) | 2017-04-28 | 2018-11-01 | Aduro Biotech, Inc. | Bis 2'-5'-rr-(3'f-a)(3'f-a) cyclic dinucleotide compound and uses thereof |
WO2018210793A3 (en) * | 2017-05-16 | 2018-12-20 | Synthon Biopharmaceuticals B.V. | ANTI-SIRPα ANTIBODIES |
US11274159B2 (en) | 2017-05-16 | 2022-03-15 | Byondis B.V. | Anti-SIRPα antibodies |
EP4400173A2 (en) | 2017-05-16 | 2024-07-17 | Byondis B.V. | Anti-sirp alpha antibodies |
TWI710574B (en) * | 2017-05-16 | 2020-11-21 | 荷蘭商拜恩迪斯公司 | ANTI-SIRPα ANTIBODIES |
RU2771174C2 (en) * | 2017-05-16 | 2022-04-28 | Байондис Б. В. | ANTI-SIRPα ANTIBODIES |
WO2018210795A1 (en) | 2017-05-16 | 2018-11-22 | Synthon Biopharmaceuticals B.V. | ANTI-SIRPα ANTIBODIES |
WO2018210793A2 (en) | 2017-05-16 | 2018-11-22 | Synthon Biopharmaceuticals B.V. | ANTI-SIRPα ANTIBODIES |
US11718681B2 (en) | 2017-05-16 | 2023-08-08 | Byondis B.V. | Anti-SIRP α antibodies |
WO2019022600A1 (en) * | 2017-07-24 | 2019-01-31 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction |
EP3747438A1 (en) * | 2017-07-24 | 2020-12-09 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction |
EP3747437A1 (en) * | 2017-07-24 | 2020-12-09 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction |
AU2018308191B2 (en) * | 2017-07-24 | 2023-12-21 | Scenic Immunology B.V. | Treating pathological conditions by direct and indirect targeting of SIRPa - CD47 interaction |
US11753480B2 (en) | 2017-07-26 | 2023-09-12 | Forty Seven, Inc. | Anti-SIRP-alpha antibodies and related methods |
WO2019023347A1 (en) | 2017-07-26 | 2019-01-31 | Forty Seven, Inc. | Anti-sirp-alpha antibodies and related methods |
KR102670957B1 (en) | 2017-07-26 | 2024-05-31 | 포티 세븐, 인코포레이티드 | Anti-SIRP-alpha antibodies and related methods |
KR20200067833A (en) * | 2017-07-26 | 2020-06-12 | 포티 세븐, 인코포레이티드 | Anti-SIRP-alpha antibodies and related methods |
US10961318B2 (en) | 2017-07-26 | 2021-03-30 | Forty Seven, Inc. | Anti-SIRP-α antibodies and related methods |
US11401329B2 (en) | 2017-08-02 | 2022-08-02 | Phanes Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
WO2019073080A1 (en) * | 2017-10-13 | 2019-04-18 | Ose Immunotherapeutics | Modified anti-sirpa antibodies and uses thereof |
CN111511766A (en) * | 2017-10-13 | 2020-08-07 | Ose免疫疗法 | Modified anti-SIRPa antibody and application thereof |
CN111511766B (en) * | 2017-10-13 | 2024-06-07 | Ose免疫疗法 | Modified anti-SIRPa antibodies and uses thereof |
US11713356B2 (en) | 2017-10-13 | 2023-08-01 | Ose Immunotherapeutics | Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer |
US11802153B2 (en) | 2017-10-18 | 2023-10-31 | Forty Seven, Inc. | Anti-CD47 agent-based ovarian cancer therapy |
WO2019141732A1 (en) * | 2018-01-16 | 2019-07-25 | Argenx Bvba | Cd70 combination therapy |
EP4275702A3 (en) * | 2018-01-16 | 2024-02-28 | Argenx BVBA | Cd70 combination therapy |
CN111836830A (en) * | 2018-01-16 | 2020-10-27 | 阿根思公司 | CD70 combination therapy |
US11530271B2 (en) | 2018-01-16 | 2022-12-20 | argenx BV | CD70 combination therapy |
US11891450B2 (en) | 2018-02-12 | 2024-02-06 | Forty Seven, Inc. | Anti-CD47 agent-based treatment of CD20-positive cancer |
US11884723B2 (en) | 2018-03-13 | 2024-01-30 | Ose Immunotherapeutics | Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies |
WO2019175218A1 (en) | 2018-03-13 | 2019-09-19 | Ose Immunotherapeutics | Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies |
CN112105646A (en) * | 2018-03-13 | 2020-12-18 | Ose免疫疗法 | Use of anti-human SIRPa v1 antibody and method for producing anti-SIRPa v1 antibody |
US11292850B2 (en) | 2018-03-21 | 2022-04-05 | ALX Oncology Inc. | Antibodies against signal-regulatory protein α and methods of use |
US11939393B2 (en) | 2018-03-21 | 2024-03-26 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
EP4144372A2 (en) | 2018-03-21 | 2023-03-08 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
US11319373B2 (en) | 2018-05-25 | 2022-05-03 | Alector Llc | Anti-SIRPA antibodies and methods of use thereof |
WO2019226973A1 (en) | 2018-05-25 | 2019-11-28 | Alector Llc | Anti-sirpa antibodies and methods of use thereof |
US11976119B2 (en) | 2018-05-25 | 2024-05-07 | Alector Llc | Anti-SIRPa antibodies and methods of use thereof |
US12060422B2 (en) | 2018-06-29 | 2024-08-13 | Alector Llc | Anti-SIRP-Beta1 antibodies and methods of use thereof |
US12084497B2 (en) | 2018-08-08 | 2024-09-10 | Orionis Biosciences, Inc. | SIRP1α targeted chimeric proteins and uses thereof |
US12084499B2 (en) | 2018-09-27 | 2024-09-10 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
CN113286613A (en) * | 2018-10-29 | 2021-08-20 | Umc乌得勒支控股有限公司 | IgA mediated killing of abnormal cells by CD47-SIRP alpha checkpoint inhibition of neutrophils |
GB2593632A (en) * | 2018-10-29 | 2021-09-29 | Umc Utrecht Holding Bv | IGA mediated killing of aberrant cells by CD47-Sirpalpha checkpoint inhibition of neutrophils |
WO2020091596A1 (en) | 2018-10-29 | 2020-05-07 | Umc Utrecht Holding B.V. | Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils |
GB2593632B (en) * | 2018-10-29 | 2023-05-24 | Umc Utrecht Holding Bv | IGA mediated killing of aberrant cells by CD47-Sirpalpha checkpoint inhibition of neutrophils |
WO2020099653A1 (en) | 2018-11-15 | 2020-05-22 | Byondis B.V. | HUMANIZED ANTI-SIRPα ANTIBODIES |
WO2020112870A1 (en) | 2018-11-28 | 2020-06-04 | Forty Seven, Inc. | Genetically modified hspcs resistant to ablation regime |
US11712468B2 (en) | 2018-12-18 | 2023-08-01 | argenx BV | CD70 combination therapy |
US11555073B2 (en) | 2018-12-20 | 2023-01-17 | 23Andme, Inc. | Anti-CD96 antibodies and methods of use thereof |
US11059909B2 (en) | 2019-03-27 | 2021-07-13 | Umc Utrecht Holding B.V. | Engineered IgA antibodies and methods of use |
US11091562B2 (en) | 2019-03-27 | 2021-08-17 | Umc Utrecht Holding B.V. | Engineered IGA antibodies and methods of use |
WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
EP4349413A2 (en) | 2019-10-18 | 2024-04-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
WO2021076908A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
WO2021087064A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
CN114040925A (en) * | 2019-12-24 | 2022-02-11 | 礼新医药科技(上海)有限公司 | anti-SIRP alpha monoclonal antibody and application thereof |
WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
CN114040925B (en) * | 2019-12-24 | 2023-04-28 | 礼新医药科技(上海)有限公司 | anti-SIRP alpha monoclonal antibody and application thereof |
WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
WO2022219076A1 (en) | 2021-04-14 | 2022-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to improve the anti-tumoral activity of macrophages |
WO2022221304A1 (en) | 2021-04-14 | 2022-10-20 | Gilead Sciences, Inc. | CO-INHIBITION OF CD47/SIRPα BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
WO2022254379A1 (en) | 2021-06-04 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Anti-sirp-alpha antibodies |
US11572412B2 (en) | 2021-06-04 | 2023-02-07 | Boehringer Ingelheim International Gmbh | Anti-SIRP-alpha antibodies |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023278377A1 (en) | 2021-06-29 | 2023-01-05 | Seagen Inc. | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
WO2023020459A1 (en) | 2021-08-17 | 2023-02-23 | 杭州九源基因工程有限公司 | MONOCLONAL ANTIBODY TARGETING SIRPα AND USE THEREOF |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023094698A1 (en) | 2021-11-29 | 2023-06-01 | Ose Immunotherapeutics | Specific antagonist anti-sirpg antibodies |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023147418A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | Parp7 inhibitors |
WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2023196784A1 (en) | 2022-04-05 | 2023-10-12 | Gilead Sciences, Inc. | Combinations of antibody therapies for treating colorectal cancer |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
AU2015229448A1 (en) | 2016-09-01 |
US10781256B2 (en) | 2020-09-22 |
US20170073414A1 (en) | 2017-03-16 |
AU2015229448B2 (en) | 2020-09-03 |
JP6606505B2 (en) | 2019-11-13 |
SG11201607143UA (en) | 2016-09-29 |
EP3116544A4 (en) | 2017-08-23 |
WO2015138600A3 (en) | 2015-11-26 |
CA2939293C (en) | 2023-10-03 |
CN106456749A (en) | 2017-02-22 |
US20180319883A1 (en) | 2018-11-08 |
CN106456749B (en) | 2021-03-30 |
CA2939293A1 (en) | 2015-09-17 |
EP3116544A2 (en) | 2017-01-18 |
JP2017510251A (en) | 2017-04-13 |
US10081680B2 (en) | 2018-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10781256B2 (en) | Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies | |
JP7199494B2 (en) | Humanized and Chimeric Monoclonal Antibodies Against CD47 | |
US11718675B2 (en) | Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy | |
JP7153626B2 (en) | Anti-human 4-1BB antibody and uses thereof | |
JP2021525243A (en) | Compositions and Methods for Promoting Killing of Target Cells by NK Cells | |
WO2020098734A1 (en) | Anti-tigit antibody and use thereof | |
KR20180095086A (en) | Humanized, mouse or chimeric anti-CD47 monoclonal antibody | |
JP7257971B2 (en) | Anti-CD40 Antibodies, Antigen-Binding Fragments Thereof, and Medical Uses Thereof | |
CA3156983A1 (en) | Antibodies against the poliovirus receptor (pvr) and uses thereof | |
CN114667296B (en) | Bispecific antibody and application thereof | |
JP2023524102A (en) | Antibodies specific for ABCB5 and uses thereof | |
US10815306B2 (en) | Humanized and chimeric monoclonal antibodies to CD81 | |
CN115996951A (en) | anti-CD 103 antibodies | |
JP2022514615A (en) | Antagonist antibody against human immune checkpoint CEACAM1 (CD66a), its preparation, kit and usage | |
WO2023040940A1 (en) | Use of pvrig/tigit binding protein in combination with immune checkpoint inhibitor in treatment of cancers | |
JP2023551907A (en) | Tumor-associated antigens and CD3 binding proteins, related compositions, and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15762121 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2016551302 Country of ref document: JP Kind code of ref document: A Ref document number: 2939293 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15122560 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2015229448 Country of ref document: AU Date of ref document: 20150311 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015762121 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015762121 Country of ref document: EP |